

Cancer Incidence and Mortality in New Jersey 2002 - 2006

Prepared by:
Xiaoling Niu, MS
Stasia S. Burger, MS, CTR
Karen Pawlish, ScD, MPH
Kevin A. Henry, PhD

Cancer Epidemiology Services
Public Health Services Branch
New Jersey Department of Health and Senior Services

Christina G. Tan, MD
State Epidemiologist

Susan Walsh, MD, FACP
Deputy Commissioner

Heather Howard
Commissioner

Jon S. Corzine
Governor

Cancer Epidemiology Services
New Jersey Department of Health and Senior Services
PO Box 369
Trenton, NJ 08625-0369
(609) 588-3500

<http://nj.gov/health/ces/index.shtml>

February 2009

ACKNOWLEDGMENTS

The following staff of the New Jersey State Cancer Registry and the Cancer Surveillance Program of the Cancer Epidemiology Services were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

Toshi Abe, MCW, CTR	Betsy A. Kohler, MPH, CTR
Pamela Agovino, MPH	Fran Krol, CTR
Tara Blando, MPH	Mireille Lemieux, CTR
Donna Brown-Horn, CTR	Henry Lewis, MPH
Kathleen Diszler, RN, CTR	Helen Martin, CTR
Thomas English, CTR	Ilsia Martin, MS
Angela Feng	Kevin Masterson, CTR
Lorraine Fernbach, CTR	Carl C. Monetti
Ruthann Filipowicz	John Murphy, CTR
Raj Gona, MPH, MA	Lisa Paddock, MPH
Maria Halama, MD, CTR	Maithili Patnaik, CTR
Essam Hanani, MD, CTR	Theresa Pavlovcak, CTR
Denise Hansen	Karen Pawlish, MPH, ScD
Marilyn Hansen, CTR	Gladys Pyatt-Dickson, CTR
Joan Hess, RN, CTR	Karen Robinson-Fraser, CTR
Yvette Humphries	Lisa M. Roche, MPH, PhD
Nicole Jackson	Marcelina Rosario
Jamal Johnson, CTR	Antonio Savillo, MD, CTR
Linda Johnson, CTR	Suzanne Schwartz, MS, CTR
Catherine Karnicky, CTR	Celia Troisi, CTR
Harrine Katz, CTR	Susan Van Loon, RN, CTR
Joan Kay, CTR	Homer Wilcox III, MS

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract HHSN261200544005C ADB No. N01-PC-54405, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement 1 U58/DP000808, and the State of New Jersey.

TABLE OF CONTENTS

Introduction.....	1
Summary.....	2
Technical Notes.....	4
New Jersey State Cancer Registry.....	4
Data Sources and Specifications.....	6
Data Presentation.....	9
References.....	11

TABLES

Table 1. Age-adjusted Incidence Rates, Males (all races combined).....14

Table 2. Age-adjusted Incidence Rates, Females (all races combined).....16

Table 3. Age-adjusted Incidence Rates, White Males.....18

Table 4. Age-adjusted Incidence Rates, White Females.....20

Table 5. Age-adjusted Incidence Rates, Black Males.....22

Table 6. Age-adjusted Incidence Rates, Black Females.....24

Table 7. Age-adjusted Incidence Rates, Hispanic Males and Females (combined years)...26

Table 8. Benign and Borderline Brain Tumor Incidence Rates, 2004-2006.....28

Table 9. Comparative Incidence Rates, New Jersey and U.S., 2001-2005: Males.....29

Table 10. Comparative Incidence Rates, New Jersey and U.S., 2001-2005: Females.....29

Table 11. Age-adjusted Mortality Rates, Males (all races combined).....30

Table 12. Age-adjusted Mortality Rates, Females (all races combined).....32

Table 13. Age-adjusted Mortality Rates, White Males.....34

Table 14. Age-adjusted Mortality Rates, White Females.....36

Table 15. Age-adjusted Mortality Rates, Black Males.....38

Table 16. Age-adjusted Mortality Rates, Black Females.....40

Table 17. Age-adjusted Mortality Rates, Hispanic Males and Females (combined years)...42

Table 18. Comparative Mortality Rates, New Jersey and U.S., 2001-2005: Males.....44

Table 19. Comparative Mortality Rates, New Jersey and U.S., 2001-2005: Females.....44

Table 20. Population Denominators.....45

Table 21. Age Distribution of Cancer Incidence Cases.....47

Table 22. Median Age at Cancer Diagnosis.....48

INTRODUCTION

This report presents statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 2002-2006, age-adjusted mortality rates and counts for the period 2002-2005 and comparisons of state and national rates for 2001-2005. The New Jersey cancer incidence data for 2006 are considered preliminary. U.S. cancer incidence data and cancer mortality data for 2006 are not yet available.

The primary goal of this report is to provide 2002-2006 cancer data to healthcare planners, researchers and the public. Data are provided statewide for six population subgroups: white men, white women, black men, black women, Hispanic men and Hispanic women. Data are also provided by gender for all races combined.

For each year, the age-adjusted incidence and mortality rates per 100,000 population are shown for 69 categories of cancer and for all sites combined. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the data tables. These conventions are standard practice for publication of cancer rates in the United States. According to public law, benign and borderline brain tumors diagnosed on or after January 1, 2004 are required to be reported to cancer registries and preliminary incidence data for 2004-2006 are presented here for the first time in this report in Table 8.

Additional New Jersey cancer incidence, mortality, survival, and prevalence data are available from the Cancer Epidemiology Services office or on our website, <http://nj.gov/health/ces/index.shtml>, including:

- *Childhood Cancer in New Jersey, 1979-2005*;
- *Area Socioeconomic Variations in Cancer Incidence and Stage at Diagnosis in New Jersey, 1996-2002*;
- *Cancer Survival in New Jersey 1979-1999*;
- *Cancer Prevalence in New Jersey on January 1, 2003*;
- *Cancer Incidence Rates in New Jersey's Ten Most Populated Municipalities 1998-2002*; and
- *Trends in Cancer Incidence and Mortality in New Jersey 1979-2002*.

Our interactive cancer data mapping application provides incidence counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 1990-2006 and mortality counts and rates for the years 2001-2005 at <http://www.cancer-rates.info/nj/>. Other New Jersey and U.S. cancer data can be found on the following websites:

- Cancer Control Planet, <http://cancercontrolplanet.cancer.gov/>
- North American Association of Central Cancer Registries' *Cancer in North America 2001—2005*, <http://www.naaccr.org/cancerinnorthamerica>
- Surveillance, Epidemiology and End Results Program (SEER) Cancer Statistics, <http://surveillance.cancer.gov/statistics/>

SUMMARY

NEW JERSEY CANCER INCIDENCE AND MORTALITY DATA, 2002-2006

A total of 46,569 cases of invasive cancer diagnosed in 2006 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), compared to 45,052 reported cases diagnosed in 2005. During the period 2002-2006, a total of 230,667 cases of invasive cancer were diagnosed among New Jersey residents, 51 percent among men and 49 percent among women.

The top primary cancers with the highest age-adjusted incidence rates in 2002-2006 in New Jersey were prostate, lung, colon and rectum, urinary bladder, melanoma of the skin, non-Hodgkin lymphoma, and kidney and renal pelvis for men and breast, lung, colon and rectum, uterine (corpus and uterus, NOS), non-Hodgkin lymphoma, thyroid, and melanoma of the skin for women.

In New Jersey, the overall age-adjusted total cancer incidence rates for men declined during 2002 to 2005 but increased in 2006 as a result of increased prostate cancer incidence. Overall prostate cancer incidence rates decreased from 2002 to 2004 but increased in 2005 and 2006 for reasons currently not known. The total cancer incidence rates for black men declined from 2002 to 2006 and were lower than white men in 2006 for the first time in New Jersey since the NJSCR started collecting data. The lung cancer incidence rates among men declined, especially for black men, whose rates greatly declined to below that of white men for 2006. Colon and rectum cancer incidence rates also declined among men and women. Incidence rates for liver and intrahepatic bile duct cancer among men continued to slowly increase.

The age-adjusted total cancer incidence rates for New Jersey women remained stable from 2002 through 2006. Black women had lower incidence rates compared to white women. Breast cancer incidence rates among all women declined from 2002 to 2006 while lung cancer incidence rates continue to level off. Incidence rates for thyroid cancer and melanoma of the skin among women increased statewide, especially for white women.

New Jersey Hispanics continued to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population including lung, colorectal, breast, bladder, and melanoma of the skin. Hispanics also continued to have higher incidence rates for cervical, stomach and liver cancers compared with the general population.

A preliminary review of the incidence of benign and borderline brain and central nervous system tumors in New Jersey showed that they occurred mostly in intracranial meninges and the sellar region, while invasive brain tumors occurred mostly in the brain proper. This pattern was similar to the results seen in U.S. SEER data. New Jersey incidence data for 2004-2006 showed women had slightly higher rates compared to men for these types of tumors and rates were similar among whites and blacks. Women also had higher benign intracranial meningioma incidence rates compared to men for this same time period.

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in North America* by the North American Association of Central Cancer Registries (NAACCR) for 2001-2005, New Jersey incidence rates for all cancers combined continued to be higher than U.S. rates. New Jersey had higher incidence rates compared to U.S. for the most common cancers with a few exceptions. New Jersey lung cancer incidence rates were lower than U.S. rates among white, black and all men combined and New Jersey melanoma incidence rates were similar to the U.S. rates among black men and women.

Among New Jersey residents, a total of 17,171 deaths occurred in 2005 for which cancer was designated on the death certificate as the underlying cause, compared to 17,206 reported cancer deaths in 2004. During the period 2002-2005, a total of 70,161 cancer deaths occurred among New Jersey residents, 49 percent among men and 51 percent among women. The top cancers with the highest age-adjusted mortality rates for 2002-2005 in New Jersey were lung, prostate, and colon and rectum for men; and lung, breast, and colon and rectum for women. Overall age-adjusted cancer mortality rates in New Jersey continued to decline, reflecting the recent trends seen in U.S. mortality data.

New Jersey cancer mortality rates continued to be higher for men than for women. Cancer mortality rates for blacks continued to be higher than for whites for both men and women. Overall cancer mortality rates for New Jersey Hispanic men and women were lower than for all men and women except for slightly higher mortality rates for stomach cancer. Mortality rates were generally higher for Hispanic men compared with Hispanic women, which is consistent with the pattern seen among all races/ethnicities combined.

For the period 2001-2005, the cancer mortality rates for all cancer sites combined, lung, and prostate for New Jersey men were lower than the corresponding rates for the U.S. The colorectal cancer mortality rates for New Jersey men were slightly higher than for U.S. men. Black men in New Jersey had lower mortality rates for all cancers combined, lung cancer, prostate cancer, and colorectal cancer compared to the U.S. black men. Among New Jersey women for the same time period, the cancer mortality rates for all sites combined, breast and colorectal cancers were higher compared to U.S. women. Lung cancer mortality rates for New Jersey women were similar to the corresponding rates for the U.S.

TECHNICAL NOTES

New Jersey State Cancer Registry (NJSCR)

NJSCR Overview

The objectives of the New Jersey State Cancer Registry (NJSCR) are to:

- * monitor cancer trends in New Jersey;
- * promote scientific research;
- * respond to New Jersey residents about cancer concerns;
- * educate the public;
- * provide information for planning and evaluating cancer prevention and control activities; and
- * share and compare cancer data with other states and the nation.

The NJSCR is a population-based cancer incidence registry that serves the entire state of New Jersey, which has a current estimated population of over 8.6 million people. The NJSCR was established by legislation (NJSA 26:2-104 et. seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (NJAC 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, reporting agreements are maintained with New York, Pennsylvania, Delaware, Florida, Maryland, and North Carolina so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the Registry by: requiring electronic reporting; requiring abstracting by certified tumor registrars; and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. Benign and borderline brain tumors diagnosed on or after January 1, 2004 are required to report according to Public Law 107-260, the Benign Brain Tumor Cancer Registries Act which was signed in October 2002. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) determined annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O)*, 3rd edition for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the NAACCR, an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a

participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a National Cancer Institute (NCI) SEER Registry.

NJSCR Data Quality

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each year 1995 through 2005. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulas, it is possible for the estimation of completeness to be greater than 100 percent. For 2006 data, the completeness of case reporting was estimated as 108 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the cancer rates, or alter the overall trends presented in this report.

Other 2006 cancer incidence data quality indicators measured as follows:

- percent death-certificate-only cases: 1.4 percent;
- percent of unresolved duplicates: < 0.1 percent;
- percent of cases with unknown race: 1.7 percent;
- percent of cases with unknown county: 0.05 percent;
- number of cases with unknown age: 4; and
- number of cases with unknown gender: 1.

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to delayed reporting, ongoing editing and reviewing of the data. The 2005 incidence rate for total cancer in this report increased by 1.7% for men and 1.4% for women compared with last year's report. The 2006 incidence rates are considered preliminary since case counts are expected to change by the time all data are complete.

The NJSCR continues to work toward improving the quality and number of its reporting sources. Over the past few years, significant improvements have been realized in this regard. For example, some of these improvements have resulted in better reporting of skin cancers such as melanoma. One of the most significant improvements has been the implementation of electronic pathology laboratory reporting (E-path) from a national pathology laboratory and several

hospital-based laboratories. The ultimate goal is to enable E-path laboratory reporting from every laboratory that serves New Jersey. E-path reporting has improved the timeliness and completeness of cancer reporting, especially for non-hospitalized cases.

One limitation that could affect New Jersey cancer incidence data is the recent federal formal restrictions on the submission of cancer cases from Veteran's Health Administration (VA) hospitals to cancer registries. NJSCR received 0.6% of the total cases exclusively from VA hospitals for the years 2004 and earlier. Since then, the NJSCR received only 0.3% of the total cases from VA hospitals for 2005 and no cases for 2006. The impact of missing VA hospital cases in New Jersey could result in underestimates of cancer incidence rates for men in 2005 and 2006.

Data Sources and Specifications

Incidence Data

New Jersey cancer incidence data were taken from the December 2008 analytic file of the New Jersey State Cancer Registry. All the counts and rates were tabulated using SEER*Stat Version 6.4 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America 2001-2005* (<http://www.naacr.org/cancerinnorthamerica>).

The cancer categories in this report are based on the primary site and histology data fields abstracted from the medical records. For detailed definitions of the cancer categories, please visit SEER program website (http://www.seer.cancer.gov/siterecode/icdo3_d01272003/). We used the cancer site recode with mesothelioma and Kaposi sarcoma in separate categories.

The coding scheme for incident cancer cases in this report is derived from *International Classification of Diseases for Oncology, 3rd edition (ICD-O-3)*. There are some reportability changes from ICD-O-2 to ICD-O-3. When cases in 1979-2000 are converted from ICD-O-2 to ICD-O-3, some cancers (mainly ovarian cancer) yield an ICD-O-3 borderline behavior. Also, when 2001+ cases are converted from ICD-O-3 to ICD-O-2, some cancers yield an ICD-O-2 borderline behavior. We used SEER behavior recode for analysis to select invasive cancers. For the definition, visit SEER Behavior Recode for Analysis on SEER web site: <http://www.seer.cancer.gov/behavrecode/>. Using this definition, only those invasive cancers had a behavior of malignant in both ICD-O-2 and ICD-O-3 are presented in the tables except the benign and borderline brain tumor table.

Exclusions

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 2002-2006 is 120, representing 0.05% of the total case population. The small numbers of cases with unknown age or gender were also excluded from the analyses. Since the number of records affected was very small, the rates were virtually unaffected by the non-inclusion of these records. Race-specific information is not shown separately for persons who are races other than white or black (including unknown race), but these persons are included in the "all races" data.

Only invasive cancers were included in the incidence tables 1 to 7, 9-10 and 21-22, except *in situ* bladder cancers were included. Invasive means that a case had malignant behavior in both ICD-O-2 and ICD-O-3. Some cancers were excluded from the analysis by this definition.

Myelodysplastic syndrome, for example, was reclassified in ICD-O-3 (effective diagnosis year 2001) from nonmalignant to malignant; other cancers so reclassified include endometrial stromal sarcoma (low grade), papillary ependymoma, papillary meningioma, polycythemia vera, chronic myeloproliferative disease (NOS), myelosclerosis with myeloid metaplasia, essential thrombocythemia, refractory anemia, refractory anemia with sideroblasts, refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation. In contrast, borderline tumors of the ovary were reclassified from malignant to nonmalignant at the same time. These cancers were excluded from the analysis. Starting with diagnosis year 2001, pilocytic astrocytoma was reclassified as malignant and was not excluded.

Mortality Data

New Jersey cancer mortality data in 2002-2005 were obtained through the NCI's SEER Program from the National Center for Health Statistics (NCHS) and tabulated using SEER*Stat. At the time of this report, year 2006 mortality data were not yet available.

Cancer sites in mortality data were grouped according to the revised SEER Cause of Death Recode 1969+ (9/17/2004). The detailed information can be found on SEER web site (<http://seer.cancer.gov/codrecode/>). U.S. cancer mortality data were obtained from NAACCR's publication, *Cancer in North America 2001-2005* (<http://www.naacr.org/cancerinnorthamerica>).

Population Data

The 2001-2006 New Jersey population estimates for this report were provided by the NCI's SEER Program release on November 19, 2008 and downloaded from the SEER's website (<http://www.seer.cancer.gov/popdata/download.html>). The population estimates represent a modification of the Vintage 2007 annual time series of July 1 county population estimates by age, sex, race and Hispanic origin produced by the U.S. Census Bureau's Population Estimates Program (<http://www.census.gov/popest/counties/asrh>) in collaboration with the NCHS, and with support from the NCI through an interagency agreement. The Vintage 2007 postcensal population estimates were produced after implementation of several methodologic changes by the Census Bureau. The net impact of the various methodologic changes is a downward shift of the Vintage 2007 postcensal population estimates when compared to those from the Vintage 2006 series. A downward shift in the net international migration estimates accounts for most of the change in the Vintage 2007 estimates.

In the 2000 Census, individuals were given the opportunity to categorize themselves as more than one race, as specified in the 1997 Office of Management and Budget (OMB) standards (http://www.whitehouse.gov/omb/fedreg/directive_15.html) for the collection of data on race and ethnicity. For the first time, individuals could "mark [X] one or more races to indicate what this person considers himself/herself to be." The population estimates incorporate new bridged single-race estimates for July 1, 2000 to July 1, 2006 that are derived from the original multiple

race categories in the 2000 Census. These estimates result from bridging the 31 race categories used in Census 2000 to the four single race categories specified under the 1977 OMB standards. Race bridging is a method used to make multiple-race and single-race data collection systems sufficiently comparable to permit estimation and analysis of race-specific statistics. The bridged single-race estimates and a description of the methodology used to develop them appear on the NCHS website (<http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>).

Description of Algorithm for Designating Hispanic Ethnicity

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry during the years 1994-2005.

In 2005, NAACCR made several revisions to NHIA, now NHIA version 2. The most significant change in NHIA version 2 was the addition of an option for registries to not apply the algorithm to counties in which the Hispanic population is less than five percent. The New Jersey State Cancer Registry determined that this option did not enhance the accuracy of the NHIA and therefore opted not to apply this option. Thus, using NHIA version 2 will not affect the New Jersey cancer rates among Hispanics.

Prior to the development of the NHIA, the NJSCR used a method to assign Hispanic ethnicity to cases that was adapted from algorithms developed by the Illinois State Cancer Registry (ISCR) and by the NJSCR. NHIA is closely related to these former algorithms, so there is high agreement between the cases previously determined to be Hispanic and those currently determined to be Hispanic.

As a result of using the NHIA, the NJSCR was able to increase the number of Hispanic cases by 23 percent for this time period, thereby correcting an under-identification of Hispanics. For a more complete description of the NHIA version 2 and a copy of the NHIA SAS program visit the following link at the NAACCR website: <http://www.naacrr.org/datastandards>.

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g. black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority (89 percent) of Hispanics identify themselves as white. The Hispanics who identify themselves as white or black are included in the white or black race category as well as the all races category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the NHIA algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13 percent for men and 23 percent for women.

Data Presentation

Suppression of Rates and Counts under Five

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, rates were suppressed where counts were less than five as a way to ensure statistical reliability and patient confidentiality.

Calculation of Rates

All the counts and rates were tabulated using SEER*Stat Version 6.4 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 2001-2005* (<http://www.naacr.org/cancerinnorthamerica>).

Age-adjusted Rates and the Year 2000 Standard

The U.S. Department of Health and Human Services requires that health data be age-adjusted using the U.S. Year 2000 population as a standard, beginning with the 1999 reporting year. Age-adjustment to the year 2000 population as the standard has been used in our last six annual reports. Prior to the release of 1999 data, various federal and state agencies calculated disease rates using different U.S. population standards, including the 1940 and 1970 standard populations. Our report *Cancer Incidence and Mortality in New Jersey, 1995-1999*, issued in September 2001, used the former 1970 population standard for all five years and also illustrated the effect on 1999 incidence rates of changing the population standard from 1970 to 2000.

Calculations using the 2000 standard population do not indicate a change in cancer incidence or occurrence—only a different representation of the rates of reported cancer. Using the 2000 population as the standard produces standardized cancer rates that appear to be about 20 percent higher than previously reported.

In this report, the 2000 U.S. Standard Population (19 age groups-Census P25-1130) was used for age-adjustment instead of the 2000 U.S. Standard Million (19 age groups). This has been standard practice for all NCI SEER reports with incidence or mortality data for 2002 or later. This new population standard was created for use with single year of age population data. Differences in the age-adjusted rates using the 2000 Standard Million and the new 2000 U.S. Standard Population are minimal. For further details, see SEER's website located at the following link: http://seer.cancer.gov/stdpopulations/single_age.html.

Rate Calculation Formulas

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where

- r_a = the age-specific rate for age group a,
- n_a = the number of events (cancer diagnoses) in the age group during the time interval,
- t = the length of the time interval (in years), and
- P_a = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization, which uses the following formula:

$$R = \frac{\sum_{a=1}^n r_a \times Std. P_a}{\sum_{a=1}^n Std. P_a}$$

where

- R = the age-adjusted rate,
- r_a = the age-specific rate for age group a, and
- $Std.P_a$ = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

REFERENCES

Breslow NE and Day NE. *Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies*. New York: Oxford University Press, 1987.

Chiang CL. "Standard error of the age-adjusted death rate". In *Vital Statistics Special Reports, Volume 47, Number 9*. USDHEW, PHS, Washington, D.C. U.S. Government Printing Office, 1961.

Fritz A., Percy C. *Implementing ICD-O-3: Impact of the New Edition*. SEER Program, National Cancer Institute. [URL. http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf], accessed October 26, 2005]

Howe HL, Lake A, Firth R, et al.(eds). *Cancer in North America, 2001-2005. Volume One: Combined Cancer Incidence for the United States and Canada*. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2008.

Ingram DD, Parker JD, Schenker N et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. *Vital Health Stat* 2(135). 2003. [URL. http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf, accessed October 26, 2005]

Jemal A, Thun MJ, Ries LAG, et al. Annual Report to the Nation on the Status of Cancer, 1975-2005, Featuring Trends in Lung Cancer, Tobacco Use and Tobacco Control. *J Natl Cancer Inst*; Dec. 2, 2008;100(23).

Martin, RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population". *Topics in Health Statistics*. Center for Health Statistics. 2000;01-02.

National Center for Health Statistics. U.S. census population with bridged race categories, August 2008. [URL. <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>, accessed November 12, 2008]

North American Association of Central Cancer Registries. *Registry Operation Guidelines-Hispanic Identification*. Springfield, Illinois: U.S. [URL. <http://www.naacr.org/datastandards>, accessed October 26, 2006]

Rothman K. *Modern Epidemiology*. U.S. Little, Brown, and Company. 1986.

Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.4.4. April 24, 2008.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2005) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov)
SEER*Stat Database: Populations - Total U.S. (1969-2006), National Cancer Institute, DCCPS,
Surveillance Research Program, Cancer Statistics Branch, released November 2008. [URL.
<http://seer.cancer.gov/popdata/>, accessed December 1, 2008]

The United States Census Bureau. "Major differences in subject-matter content between 1990
and 2000 Census questionnaires-race", October 2003. [URL.
<http://www.census.gov/population/www/cen2000/90vs00.html>, accessed October 26, 2005]

Weinstein R, Lee YS and Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New
Jersey Department of Health and Senior Services, June 2000. [URL.
<http://www.state.nj.us/health/cancer/hispanic/>, accessed October 26, 2005]

TABLES

Table 1. Age-adjusted Incidence Rates, Males All Races Combined

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
All Sites	117,279	644.4	593.4	576.3	574.0	586.5
Oral Cavity and Pharynx	3,017	14.8	14.3	14.4	14.1	15.0
Lip	95	1.0	0.4	0.4	0.4	0.3
Tongue	954	4.3	4.4	4.5	4.2	5.1
Salivary Gland	330	1.6	1.6	1.5	1.7	1.9
Floor of Mouth	181	1.0	0.9	0.8	0.8	0.8
Gum and Other Mouth	374	1.9	1.9	1.9	1.7	1.9
Nasopharynx	171	0.9	1.0	0.5	1.0	0.6
Tonsil	461	1.9	2.1	2.2	2.1	2.2
Oropharynx	149	0.6	0.4	0.9	0.7	1.0
Hypopharynx	241	1.1	1.2	1.5	1.1	1.0
Digestive System	23,087	124.6	120.1	118.7	117.7	110.0
Esophagus	1,708	8.0	8.5	9.4	8.2	8.7
Stomach	2,495	14.4	12.7	12.8	12.8	11.8
Small Intestine	506	2.3	2.4	2.7	2.7	2.5
Colon and Rectum	12,646	72.2	67.7	64.6	64.8	57.7
Colon excluding Rectum	8,726	50.3	47.4	44.3	45.5	40.6
Rectum and Rectosigmoid Junction	3,920	21.9	20.3	20.2	19.3	17.1
Anus, Anal Canal and Anorectum	243	1.3	1.2	0.9	1.1	1.4
Liver and Intrahepatic Bile Duct	1,956	9.0	9.6	9.7	10.2	9.4
Liver	1,832	8.3	8.8	9.2	9.4	8.8
Intrahepatic Bile Duct	124	0.6	0.7	0.5	0.8	0.6
Gallbladder	203	0.9	1.4	0.9	0.8	1.3
Pancreas	2,727	13.5	13.7	14.3	14.0	14.4
Respiratory System	17,096	93.6	90.2	83.2	87.3	85.7
Larynx	1,452	7.5	7.2	6.7	6.8	7.8
Lung and Bronchus	15,407	84.7	81.8	75.5	79.4	76.9
Bones and Joints	248	1.3	1.2	1.2	1.0	1.2
Soft Tissue (Including Heart)	763	3.8	3.9	3.7	4.1	3.5
Skin (Excluding Basal and Squamous)	5,614	29.2	26.4	29.6	27.0	28.7
Melanoma of the Skin	5,223	26.9	24.8	27.6	24.9	26.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 1 (continued). Age-adjusted Incidence Rates, Males All Races Combined

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
Breast	305	1.3	1.5	1.8	1.9	1.3
Male Genital System	36,793	223.9	181.5	165.8	167.0	185.6
Prostate	35,369	216.4	174.5	158.6	161.3	179.0
Testis	1,216	6.2	5.7	6.3	4.8	5.6
Penis	162	1.1	1.1	0.7	0.6	0.7
Urinary System	13,174	65.6	65.7	70.5	68.4	70.1
Urinary Bladder (Including in situ)	8,759	44.3	44.8	48.5	46.1	47.1
Kidney and Renal Pelvis	4,158	20.0	19.8	20.8	20.8	21.2
Ureter	166	0.8	0.8	0.8	1.1	1.0
Eye and Orbit	209	1.1	1.0	1.2	0.8	1.1
Brain and Other Nervous System	1,743	8.0	9.1	7.9	8.8	8.8
Brain	1,627	7.5	8.3	7.5	8.3	8.3
Endocrine System	1,542	6.9	6.7	7.2	7.5	8.1
Thyroid	1,351	6.0	5.9	6.4	6.4	7.2
Lymphomas	5,838	29.0	30.0	29.0	29.3	28.8
Hodgkin Lymphoma	761	3.4	4.1	3.5	3.7	3.6
Non-Hodgkin Lymphoma	5,077	25.6	25.8	25.6	25.6	25.2
Myelomas	1,489	8.1	6.7	8.1	7.5	7.6
Leukemias	3,325	17.2	17.6	18.0	16.2	15.8
Lymphocytic Leukemia	1,710	8.5	8.6	9.8	8.3	8.2
Acute Lymphocytic Leukemia	390	2.1	1.3	2.1	2.0	2.0
Chronic Lymphocytic Leukemia	1,186	5.8	6.8	6.9	5.6	5.4
Myeloid and Monocytic Leukemia	1,453	7.7	8.1	7.4	7.1	6.8
Acute Myeloid Leukemia	960	5.2	4.9	5.0	4.7	4.9
Acute Monocytic Leukemia	63	0.2	0.5	0.2	0.3	0.4
Chronic Myeloid Leukemia	386	2.1	2.5	1.9	1.9	1.3
Other Leukemia	162	1.1	0.8	0.8	0.8	0.8
Mesothelioma	541	3.0	3.0	3.1	3.2	2.3
Kaposi Sarcoma	221	1.2	1.2	1.1	1.1	0.8
Ill-Defined & Unspecified Sites	2,274	11.9	13.1	11.7	11.1	11.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2. Age-adjusted Incidence Rates, Females All Races Combined

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
All Sites	113,388	450.5	439.0	447.5	441.6	441.8
Oral Cavity and Pharynx	1,523	5.9	5.9	6.4	5.5	6.3
Lip	75	0.2	0.4	0.3	0.1	0.3
Tongue	431	1.6	1.7	1.6	1.7	1.9
Salivary Gland	252	1.1	0.8	1.2	1.1	1.0
Floor of Mouth	105	0.5	0.4	0.5	0.3	0.4
Gum and Other Mouth	311	1.0	1.2	1.2	1.2	1.3
Nasopharynx	85	0.5	0.4	0.3	0.3	0.3
Tonsil	122	0.4	0.5	0.6	0.4	0.5
Oropharynx	54	0.2	0.2	0.3	0.1	0.2
Hypopharynx	65	0.3	0.2	0.3	0.2	0.3
Digestive System	21,079	82.8	81.1	78.3	77.6	74.3
Esophagus	582	2.4	2.5	2.0	1.9	2.2
Stomach	1,626	5.6	6.7	6.7	5.9	5.5
Small Intestine	484	1.8	1.9	1.8	2.0	1.9
Colon and Rectum	12,873	52.8	49.2	46.5	47.2	44.2
Colon excluding Rectum	9,670	39.5	37.2	34.6	35.3	32.4
Rectum and Rectosigmoid Junction	3,203	13.3	12.0	11.9	11.9	11.8
Anus, Anal Canal and Anorectum	416	1.5	1.5	1.7	1.8	1.6
Liver and Intrahepatic Bile Duct	817	2.9	3.1	3.3	2.9	3.2
Liver	670	2.3	2.7	2.7	2.3	2.6
Intrahepatic Bile Duct	147	0.5	0.4	0.6	0.5	0.7
Gallbladder	451	1.4	1.8	1.9	1.5	1.6
Pancreas	2,949	11.0	10.9	11.5	10.6	10.8
Respiratory System	15,075	59.0	57.7	57.0	58.7	58.1
Larynx	345	1.5	1.3	1.4	1.2	1.3
Lung and Bronchus	14,543	56.8	55.7	54.8	56.7	56.0
Bones and Joints	205	0.7	1.1	1.1	0.8	0.8
Soft Tissue (Including Heart)	727	3.1	2.8	3.3	3.0	2.8
Skin (Excluding Basal and Squamous)	4,421	17.9	15.8	17.4	19.5	19.1
Melanoma of the Skin	4,125	16.6	14.7	16.2	18.4	18.1
Breast (Invasive)	32,186	130.9	126.4	130.7	126.3	126.2
In situ (not included in All Sites)	8,996	35.3	36.9	36.2	35.1	39.2

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2 (continued). Age-adjusted Incidence Rates, Females All Races Combined

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
Female Genital System	14,035	57.1	55.2	53.9	55.1	57.8
Cervix Uteri	2,183	9.1	9.6	9.4	8.5	9.4
Corpus and Uterus, NOS	7,225	28.4	27.3	27.5	29.3	29.8
Corpus Uteri	6,991	27.7	26.3	26.6	28.5	28.9
Uterus, NOS	234	0.8	1.0	0.9	0.8	0.9
Ovary	3,659	15.6	14.6	13.6	13.8	14.6
Vagina	182	0.5	0.8	0.6	0.8	0.8
Vulva	607	2.7	2.3	2.1	2.1	2.4
Urinary System	6,063	23.4	21.2	25.0	23.4	22.8
Urinary Bladder (Including in situ)	3,253	12.1	11.3	13.6	11.9	12.1
Kidney and Renal Pelvis	2,654	10.6	9.4	10.9	10.9	10.2
Ureter	117	0.5	0.4	0.5	0.4	0.4
Eye and Orbit	150	0.5	0.6	0.6	0.7	0.7
Brain and Other Nervous System	1,400	5.3	5.9	6.7	5.6	5.4
Brain	1,262	4.8	5.1	6.1	5.1	5.0
Endocrine System	4,551	17.0	18.7	19.9	20.2	22.1
Thyroid	4,380	16.3	17.7	19.1	19.4	21.6
Lymphomas	5,247	21.3	21.3	20.8	20.5	20.4
Hodgkin Lymphoma	701	3.3	3.1	3.0	3.5	2.9
Non-Hodgkin Lymphoma	4,546	18.0	18.1	17.8	17.0	17.5
Myelomas	1,322	5.2	4.7	4.9	5.5	4.9
Leukemias	2,561	10.3	10.0	10.5	9.3	10.2
Lymphocytic Leukemia	1,256	5.3	4.7	5.2	4.8	4.7
Acute Lymphocytic Leukemia	308	1.4	1.6	1.4	1.3	1.5
Chronic Lymphocytic Leukemia	870	3.6	2.9	3.5	3.2	3.0
Myeloid and Monocytic Leukemia	1,152	4.4	4.7	4.8	3.8	5.0
Acute Myeloid Leukemia	790	3.0	3.1	3.4	2.7	3.2
Acute Monocytic Leukemia	47	0.2	0.2	0.1	0.1	0.2
Chronic Myeloid Leukemia	287	1.1	1.3	1.1	0.8	1.3
Other Leukemia	153	0.6	0.6	0.5	0.7	0.5
Mesothelioma	164	0.6	0.6	0.5	0.6	0.7
Kaposi Sarcoma	33	0.1	0.1	0.1	0.1	0.1
Ill-Defined & Unspecified Sites	2,646	9.6	9.8	10.6	9.2	9.0

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3. Age-adjusted Incidence Rates, White Males

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
All Sites	98,795	641.4	587.9	570.2	572.8	585.4
Oral Cavity and Pharynx	2,503	14.5	14.4	13.9	14.2	15.1
Lip	88	1.0	0.5	0.5	0.5	0.3
Tongue	812	4.4	4.5	4.6	4.4	5.3
Salivary Gland	289	1.7	1.8	1.4	1.8	2.1
Floor of Mouth	150	1.0	0.9	0.7	0.9	0.7
Gum and Other Mouth	303	1.8	1.9	1.9	1.5	1.8
Nasopharynx	101	0.8	0.8	0.4	0.7	0.3
Tonsil	395	1.7	2.3	2.1	2.4	2.4
Oropharynx	132	0.6	0.5	0.9	0.7	1.1
Hypopharynx	187	1.1	1.1	1.3	1.1	0.8
Digestive System	19,342	121.5	117.8	116.8	116.4	109.2
Esophagus	1,441	8.0	8.3	9.4	8.1	8.8
Stomach	1,977	13.3	11.9	11.8	11.9	11.0
Small Intestine	411	2.2	2.4	2.6	2.4	2.5
Colon and Rectum	10,799	71.8	66.9	64.9	65.0	58.3
Colon excluding Rectum	7,471	49.8	46.5	44.8	45.7	40.9
Rectum and Rectosigmoid Junction	3,328	21.9	20.4	20.1	19.3	17.3
Anus, Anal Canal and Anorectum	195	1.1	1.2	0.9	1.0	1.4
Liver and Intrahepatic Bile Duct	1,490	7.8	8.6	8.5	9.9	8.6
Liver	1,382	7.2	7.9	8.0	9.2	8.0
Intrahepatic Bile Duct	108	0.7	0.8	0.5	0.7	0.6
Gallbladder	165	0.8	1.4	0.9	0.8	1.1
Pancreas	2,346	13.6	13.9	14.3	14.0	14.6
Respiratory System	14,606	92.4	89.8	83.3	87.1	87.3
Larynx	1,200	7.1	7.2	6.5	6.7	7.6
Lung and Bronchus	13,202	83.9	81.2	75.8	79.3	78.6
Bones and Joints	194	1.2	1.2	1.2	1.1	1.2
Soft Tissue (Including Heart)	625	4.1	3.8	3.5	4.2	3.4
Skin (Excluding Basal and Squamous)	5,361	33.4	30.2	33.4	31.3	31.5
Melanoma of the Skin	5,009	31.1	28.4	31.3	29.1	29.2

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3 (continued). Age-adjusted Incidence Rates, White Males

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
Breast	258	1.3	1.5	1.8	2.0	1.2
Male Genital System	29,267	215.1	168.2	153.2	156.5	174.9
Prostate	27,958	206.1	160.0	144.8	149.8	166.9
Testis	1,125	7.6	6.9	7.5	5.8	6.9
Penis	143	1.1	1.1	0.7	0.7	0.8
Urinary System	11,884	69.5	69.8	74.1	72.4	73.2
Urinary Bladder (Including in situ)	8,088	47.8	48.8	51.3	49.4	49.9
Kidney and Renal Pelvis	3,569	20.4	19.8	21.6	21.6	21.4
Ureter	152	0.9	0.8	0.9	1.1	1.0
Eye and Orbit	193	1.2	1.2	1.2	0.9	1.3
Brain and Other Nervous System	1,547	8.6	9.8	8.9	9.5	9.4
Brain	1,449	8.3	8.9	8.4	8.9	8.8
Endocrine System	1,326	7.5	7.3	7.6	7.6	8.7
Thyroid	1,173	6.4	6.4	6.9	6.6	7.8
Lymphomas	5,024	30.1	31.2	29.9	30.1	29.8
Hodgkin Lymphoma	634	3.8	4.7	3.5	3.9	3.5
Non-Hodgkin Lymphoma	4,390	26.3	26.5	26.4	26.2	26.2
Myelomas	1,183	7.5	6.1	7.4	7.1	7.3
Leukemias	2,886	17.4	18.1	18.2	17.1	16.8
Lymphocytic Leukemia	1,490	8.5	9.1	10.0	8.7	8.9
Acute Lymphocytic Leukemia	317	2.1	1.4	2.3	2.1	2.1
Chronic Lymphocytic Leukemia	1,054	5.7	7.2	7.0	5.9	5.8
Myeloid and Monocytic Leukemia	1,261	7.8	8.2	7.4	7.6	7.2
Acute Myeloid Leukemia	848	5.2	5.1	5.2	5.2	5.2
Acute Monocytic Leukemia	56	0.2	0.5	0.3	0.3	0.4
Chronic Myeloid Leukemia	320	2.2	2.4	1.7	2.0	1.3
Other Leukemia	135	1.2	0.7	0.8	0.8	0.7
Mesothelioma	510	3.3	3.3	3.3	3.4	2.5
Kaposi Sarcoma	137	0.9	0.9	0.9	0.9	0.6
Ill-Defined & Unspecified Sites	1,949	11.9	13.1	11.6	11.1	12.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4. Age-adjusted Incidence Rates, White Females

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
All Sites	97,023	463.0	450.7	462.0	456.6	454.0
Oral Cavity and Pharynx	1,249	5.7	5.4	6.6	5.5	6.1
Lip	71	0.3	0.4	0.3	0.2	0.4
Tongue	367	1.6	1.7	1.7	1.8	1.9
Salivary Gland	199	1.0	0.8	1.2	1.0	0.9
Floor of Mouth	89	0.5	0.4	0.5	0.3	0.3
Gum and Other Mouth	259	1.1	1.0	1.3	1.2	1.2
Nasopharynx	53	0.4	0.2	0.2	0.3	0.2
Tonsil	100	0.4	0.5	0.7	0.3	0.6
Oropharynx	41	0.1	0.2	0.3	-	0.2
Hypopharynx	52	0.3	0.1	0.3	0.2	0.2
Digestive System	17,654	80.7	79.1	76.8	76.4	72.6
Esophagus	468	2.3	2.3	1.9	1.7	2.1
Stomach	1,270	5.1	6.5	6.2	5.0	4.8
Small Intestine	385	1.6	1.7	1.8	2.0	1.8
Colon and Rectum	10,895	52.1	47.8	46.3	47.1	43.6
Colon excluding Rectum	8,193	39.0	35.9	34.1	35.0	32.1
Rectum and Rectosigmoid Junction	2,702	13.1	11.8	12.2	12.1	11.5
Anus, Anal Canal and Anorectum	350	1.5	1.5	1.9	1.8	1.6
Liver and Intrahepatic Bile Duct	656	2.7	2.9	2.9	2.8	3.1
Liver	528	2.1	2.5	2.3	2.2	2.5
Intrahepatic Bile Duct	128	0.6	0.3	0.6	0.6	0.7
Gallbladder	369	1.4	1.7	1.7	1.5	1.5
Pancreas	2,511	10.5	11.0	11.4	10.7	10.8
Respiratory System	13,218	61.4	59.7	58.2	61.3	60.8
Larynx	283	1.4	1.2	1.5	1.2	1.3
Lung and Bronchus	12,779	59.2	57.8	56.0	59.2	58.7
Bones and Joints	171	0.8	1.2	1.2	0.9	0.8
Soft Tissue (Including Heart)	589	3.0	2.6	3.2	3.2	2.8
Skin (Excluding Basal and Squamous)	4,172	21.1	18.4	20.5	23.6	21.5
Melanoma of the Skin	3,919	19.7	17.3	19.3	22.5	20.4
Breast (Invasive)	27,421	135.1	131.1	136.8	130.5	130.2
In situ (not included in All Sites)	7,657	38.2	38.6	38.3	36.1	40.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4 (continued). Age-adjusted Incidence Rates, White Females

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
Female Genital System	11,905	58.8	56.7	55.7	57.2	59.6
Cervix Uteri	1,640	8.6	9.2	9.0	8.2	8.9
Corpus and Uterus, NOS	6,269	29.9	28.3	29.1	30.7	31.4
Corpus Uteri	6,080	29.3	27.2	28.2	30.0	30.5
Uterus, NOS	189	0.7	1.1	0.9	0.7	0.9
Ovary	3,189	16.4	15.3	14.3	14.9	15.3
Vagina	134	0.5	0.6	0.6	0.6	0.7
Vulva	533	2.8	2.4	2.1	2.2	2.5
Urinary System	5,321	24.4	22.0	26.4	24.5	23.2
Urinary Bladder (including in situ)	2,902	12.6	11.9	14.3	12.7	12.2
Kidney and Renal Pelvis	2,286	11.1	9.6	11.5	11.2	10.4
Ureter	107	0.6	0.4	0.5	0.5	0.4
Eye and Orbit	142	0.5	0.7	0.7	0.8	0.8
Brain and Other Nervous System	1,223	5.6	6.8	7.0	6.1	5.8
Brain	1,117	5.0	5.9	6.6	5.5	5.5
Endocrine System	3,822	18.2	19.9	21.7	21.4	23.8
Thyroid	3,691	17.6	19.1	20.9	20.5	23.3
Lymphomas	4,576	22.8	22.1	21.6	21.3	21.7
Hodgkin Lymphoma	597	3.9	3.3	3.3	3.8	3.3
Non-Hodgkin Lymphoma	3,979	18.9	18.8	18.2	17.5	18.5
Myelomas	959	4.4	4.2	4.1	4.6	4.2
Leukemias	2,164	10.2	10.3	10.5	9.4	10.4
Lymphocytic Leukemia	1,074	5.3	5.1	5.2	5.1	4.8
Acute Lymphocytic Leukemia	249	1.4	1.8	1.4	1.3	1.5
Chronic Lymphocytic Leukemia	759	3.5	3.0	3.4	3.4	3.1
Myeloid and Monocytic Leukemia	968	4.4	4.8	4.8	3.7	5.1
Acute Myeloid Leukemia	667	3.1	3.1	3.4	2.8	3.3
Acute Monocytic Leukemia	43	0.2	0.2	0.2	0.1	0.3
Chronic Myeloid Leukemia	233	0.9	1.4	1.2	0.7	1.3
Other Leukemia	122	0.6	0.5	0.5	0.6	0.5
Mesothelioma	154	0.7	0.7	0.5	0.7	0.8
Kaposi Sarcoma	27	0.1	0.1	0.1	0.1	0.1
Ill-Defined & Unspecified Sites	2,256	9.4	9.8	10.5	9.1	8.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5. Age-adjusted Incidence Rates, Black Males

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
All Sites	12,945	700.8	675.6	643.7	609.0	576.9
Oral Cavity and Pharynx	363	18.8	14.4	22.1	13.0	14.4
Lip	-	-	-	-	-	-
Tongue	105	5.2	4.4	6.4	3.2	5.4
Salivary Gland	30	1.5	-	2.4	1.0	-
Floor of Mouth	24	1.4	-	1.1	-	1.1
Gum and Other Mouth	37	2.4	1.7	1.2	1.9	1.7
Nasopharynx	31	2.0	1.1	1.3	1.7	1.0
Tonsil	60	2.8	2.3	3.9	1.5	1.9
Oropharynx	16	1.1	-	1.3	-	-
Hypopharynx	47	1.4	1.9	3.8	1.6	2.3
Digestive System	2,614	150.0	147.0	131.1	126.4	121.5
Esophagus	223	10.0	13.2	10.7	11.3	9.5
Stomach	324	21.7	16.9	17.3	16.9	16.5
Small Intestine	69	4.2	2.4	3.5	3.9	2.2
Colon and Rectum	1,331	79.8	82.4	66.7	66.9	59.1
Colon excluding Rectum	969	61.6	64.7	47.3	50.0	41.9
Rectum and Rectosigmoid Junction	362	18.2	17.7	19.4	16.9	17.3
Anus, Anal Canal and Anorectum	41	2.3	1.5	1.4	1.5	1.4
Liver and Intrahepatic Bile Duct	264	11.5	12.2	14.1	7.7	12.1
Liver	254	11.3	11.6	13.9	7.0	11.7
Intrahepatic Bile Duct	10	-	-	-	-	-
Gallbladder	24	1.5	-	-	-	2.3
Pancreas	286	15.1	15.3	14.1	14.8	16.2
Respiratory System	2,030	118.3	109.8	100.8	100.9	89.5
Larynx	216	11.2	9.1	11.5	8.9	10.4
Lung and Bronchus	1,796	106.2	100.4	88.4	90.7	78.3
Bones and Joints	35	1.3	1.3	1.0	1.2	1.1
Soft Tissue (Including Heart)	101	2.5	5.7	5.4	4.1	4.3
Skin (Excluding Basal and Squamous)	44	2.0	-	2.0	3.6	1.8
Melanoma of the Skin	21	-	-	1.6	1.9	1.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5 (continued). Age-adjusted Incidence Rates, Black Males

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
Breast	41	1.7	1.4	2.2	2.3	2.3
Male Genital System	5,264	293.7	281.8	254.0	235.9	238.1
Prostate	5,204	291.8	278.6	251.9	234.3	235.9
Testis	46	1.7	2.1	1.6	0.9	1.1
Penis	11	-	-	-	-	-
Urinary System	806	36.3	36.8	42.1	43.4	43.9
Urinary Bladder (Including in situ)	349	16.3	14.3	24.0	21.3	19.8
Kidney and Renal Pelvis	438	19.2	21.7	17.3	21.0	22.9
Ureter	7	-	-	-	-	-
Eye and Orbit	9	-	-	-	-	-
Brain and Other Nervous System	113	3.4	4.7	3.6	5.6	5.3
Brain	103	2.6	4.4	3.2	5.4	5.0
Endocrine System	103	2.8	4.0	3.0	6.5	4.3
Thyroid	81	2.7	3.4	2.6	4.4	3.5
Lymphomas	544	23.4	21.4	25.0	23.9	18.6
Hodgkin Lymphoma	93	2.3	2.2	4.5	2.8	4.0
Non-Hodgkin Lymphoma	451	21.1	19.2	20.5	21.1	14.5
Myelomas	253	14.6	13.6	16.6	11.6	9.6
Leukemias	266	14.2	14.0	15.0	11.2	9.0
Lymphocytic Leukemia	121	8.6	4.2	6.9	5.6	3.5
Acute Lymphocytic Leukemia	45	2.5	1.4	1.1	1.5	1.3
Chronic Lymphocytic Leukemia	66	6.0	2.8	3.8	3.2	2.2
Myeloid and Monocytic Leukemia	128	5.4	8.4	7.5	4.7	4.6
Acute Myeloid Leukemia	72	4.2	4.0	3.5	2.5	2.6
Acute Monocytic Leukemia	5	-	-	-	-	-
Chronic Myeloid Leukemia	47	-	3.9	3.2	2.2	1.4
Other Leukemia	17	-	1.4	-	-	-
Mesothelioma	22	-	-	1.4	2.4	-
Kaposi Sarcoma	72	2.9	2.3	3.1	2.7	1.5
Ill-Defined & Unspecified Sites	265	13.6	14.8	14.9	14.0	10.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6. Age-adjusted Incidence Rates, Black Females

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
All Sites	11,751	417.9	401.9	397.2	390.1	382.3
Oral Cavity and Pharynx	178	6.5	8.3	4.9	4.4	5.2
Lip	-	-	-	-	-	-
Tongue	36	1.1	1.5	1.0	-	1.7
Salivary Gland	37	1.4	1.1	1.0	1.5	0.9
Floor of Mouth	11	-	-	-	-	-
Gum and Other Mouth	35	1.2	2.5	-	1.0	0.8
Nasopharynx	15	-	-	-	-	-
Tonsil	18	-	0.9	-	-	-
Oropharynx	12	-	-	-	-	-
Hypopharynx	9	-	-	-	-	-
Digestive System	2,602	98.8	95.7	88.3	89.2	87.6
Esophagus	96	3.6	3.6	2.9	3.6	2.5
Stomach	246	8.5	8.1	8.8	10.4	9.2
Small Intestine	81	2.5	3.9	1.6	2.4	3.1
Colon and Rectum	1,512	59.0	56.9	49.8	50.1	50.8
Colon excluding Rectum	1,163	45.1	45.9	39.5	39.0	36.8
Rectum and Rectosigmoid Junction	349	13.9	11.0	10.2	11.1	14.0
Anus, Anal Canal and Anorectum	57	1.2	2.2	1.6	2.4	2.2
Liver and Intrahepatic Bile Duct	103	2.9	4.2	4.7	2.7	3.0
Liver	90	2.8	3.4	4.0	2.4	2.7
Intrahepatic Bile Duct	13	-	-	-	-	-
Gallbladder	58	1.0	2.8	2.4	2.0	2.3
Pancreas	363	16.3	12.0	13.7	11.6	12.2
Respiratory System	1,563	55.3	54.4	60.0	53.2	49.9
Larynx	56	3.0	2.3	1.8	1.0	1.4
Lung and Bronchus	1,488	51.7	51.7	57.4	51.5	47.6
Bones and Joints	23	-	0.9	1.1	0.7	-
Soft Tissue (Including Heart)	101	3.4	4.3	3.2	2.1	2.9
Skin (Excluding Basal and Squamous)	70	2.2	2.9	2.2	2.4	2.2
Melanoma of the Skin	33	0.9	1.5	1.3	0.8	1.4
Breast (Invasive)	3,325	117.3	107.0	104.4	108.7	107.0
In situ (not included in All Sites)	804	23.4	27.2	26.1	26.9	26.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6 (continued). Age-adjusted Incidence Rates, Black Females

Cancer Site	Total Cases	Rates				
		2002	2003	2004	2005	2006 Prelim.
Female Genital System	1,527	53.4	53.3	47.6	49.8	48.0
Cervix Uteri	409	13.5	13.0	14.2	12.1	11.9
Corpus and Uterus, NOS	669	23.9	24.3	19.5	23.8	21.2
Corpus Uteri	632	22.3	23.9	18.0	21.9	20.3
Uterus, NOS	37	1.6	-	1.5	2.0	0.9
Ovary	325	11.1	11.5	10.4	9.8	11.8
Vagina	36	-	1.6	0.8	1.5	1.5
Vulva	55	2.8	2.1	1.4	1.4	1.3
Urinary System	556	20.8	17.5	20.8	18.4	20.7
Urinary Bladder (Including in situ)	252	11.5	7.7	10.9	6.8	9.7
Kidney and Renal Pelvis	286	8.7	9.2	9.4	10.7	10.4
Ureter	7	-	-	-	-	-
Eye and Orbit	-	-	-	-	-	-
Brain and Other Nervous System	103	4.3	2.6	4.0	2.3	3.1
Brain	80	3.9	2.2	2.6	1.9	2.3
Endocrine System	349	9.1	12.0	10.6	10.7	11.6
Thyroid	321	8.3	10.8	9.7	10.0	10.9
Lymphomas	472	13.9	15.5	17.3	16.8	13.0
Hodgkin Lymphoma	79	1.5	2.9	2.6	2.9	1.9
Non-Hodgkin Lymphoma	393	12.4	12.6	14.8	13.8	11.1
Myelomas	311	12.5	8.8	11.8	12.5	9.7
Leukemias	237	7.6	7.2	8.1	7.2	9.0
Lymphocytic Leukemia	94	3.8	2.2	3.3	2.3	4.0
Acute Lymphocytic Leukemia	34	0.9	-	1.2	1.1	1.4
Chronic Lymphocytic Leukemia	57	2.9	1.6	2.0	1.1	2.5
Myeloid and Monocytic Leukemia	121	3.3	4.2	4.5	3.3	4.5
Acute Myeloid Leukemia	81	1.7	2.9	3.6	2.0	3.2
Acute Monocytic Leukemia	-	-	-	0.0	0.0	0.0
Chronic Myeloid Leukemia	35	1.3	1.0	0.8	1.3	1.1
Other Leukemia	22	-	0.9	-	1.6	-
Mesothelioma	8	-	-	-	-	-
Kaposi Sarcoma	5	-	-	-	-	-
Ill-Defined & Unspecified Sites	318	12.4	10.8	12.1	10.9	10.8

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7. Age-adjusted Incidence Rates, Hispanic Males and Females
2002-2006 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
All Sites	501.8	8,196	354.1	7,960
Oral Cavity and Pharynx	12.5	233	4.4	95
Lip	0.5	8	0.4	6
Tongue	3.7	65	1.1	26
Salivary Gland	0.7	16	0.6	15
Floor of Mouth	0.5	12	0.4	7
Gum and Other Mouth	1.6	28	0.8	17
Nasopharynx	1.0	17	0.4	10
Tonsil	2.0	45	0.4	9
Oropharynx	1.1	19	-	-
Hypopharynx	1.1	16	-	-
Digestive System	115.4	1,869	79.7	1,568
Esophagus	5.9	102	2.4	41
Stomach	18.1	295	10.4	205
Small Intestine	2.5	41	1.6	34
Colon and Rectum	58.8	936	41.6	829
Colon excluding Rectum	40.0	615	30.9	602
Rectum and Rectosigmoid Junction	18.8	321	10.6	227
Anus, Anal Canal and Anorectum	0.7	17	2.0	45
Liver and Intrahepatic Bile Duct	12.6	221	4.8	91
Liver	12.1	213	3.9	74
Intrahepatic Bile Duct	0.5	8	0.9	17
Gallbladder	1.1	20	2.9	52
Pancreas	12.3	186	10.9	208
Respiratory System	64.1	951	30.8	606
Larynx	7.0	120	0.9	19
Lung and Bronchus	55.3	800	29.2	570
Bones and Joints	1.1	35	1.3	39
Soft Tissue (Including Heart)	2.3	58	3.0	83
Skin (Excluding Basal and Squamous)	5.5	108	5.4	131
Melanoma of the Skin	4.3	82	4.6	111
Breast (Invasive)	1.2	20	94.6	2,249
In situ (not included in All Sites)	-	-	23.8	586

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males and Females
2002-2006 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
Female Genital System	*	*	51.6	1,236
Cervix Uteri	*	*	15.3	419
Corpus and Uterus, NOS	*	*	21.0	473
Corpus Uteri	*	*	19.9	449
Uterus, NOS	*	*	1.1	24
Ovary	*	*	11.4	267
Vagina	*	*	0.9	18
Vulva	*	*	2.2	42
Male Genital System	178.5	2,801	*	*
Prostate	172.9	2,613	*	*
Testis	3.9	152	*	*
Penis	1.6	34	*	*
Urinary System	46.3	681	16.4	344
Urinary Bladder (Including in situ)	30.7	398	7.3	142
Kidney and Renal Pelvis	14.2	266	8.9	196
Ureter	0.7	8	-	-
Eye and Orbit	0.9	18	0.5	11
Brain and Other Nervous System	7.5	180	4.7	125
Brain	7.2	172	4.3	113
Endocrine System	4.7	118	16.6	480
Thyroid	4.1	102	16.0	465
Lymphomas	26.1	522	20.3	471
Hodgkin Lymphoma	3.4	93	2.9	87
Non-Hodgkin Lymphoma	22.7	429	17.4	384
Myelomas	7.3	119	5.6	111
Leukemias	13.0	260	8.4	206
Lymphocytic Leukemia	5.8	129	3.6	92
Acute Lymphocytic Leukemia	2.2	78	1.8	57
Chronic Lymphocytic Leukemia	3.0	42	1.6	31
Myeloid and Monocytic Leukemia	6.3	115	4.4	104
Acute Myeloid Leukemia	4.3	75	2.7	66
Acute Monocytic Leukemia	0.3	5	0.2	5
Chronic Myeloid Leukemia	1.6	32	1.3	30
Other Leukemia	0.9	16	0.4	10
Mesothelioma	1.5	19	0.5	10
Kaposi Sarcoma	1.7	36	0.4	6
Ill-Defined & Unspecified Sites	12.1	168	9.9	189

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

* Non-applicable gender.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 8. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2004-2006

	Site Group	Cases 2004-2006	Rates		
			2004	2005	2006 Prelim.
Total	Brain	292	0.8	1.2	1.3
	Intracranial Meninges	1,426	5.2	5.3	4.8
	Cranial Nerves and other CNS	333	1.2	1.3	1.1
	Tumors of the Sellar Region	603	2.0	2.4	2.3
	Spinal Cord	149	0.4	0.6	0.7
	Spinal Meninges	113	0.5	0.3	0.4
	Total	2,916	10.2	11.1	10.7
Male	Brain	129	0.8	1.1	1.2
	Intracranial Meninges	403	3.3	3.6	3.2
	Cranial Nerves and other CNS	158	1.2	1.3	1.2
	Tumors of the Sellar Region	293	2.0	2.4	2.5
	Spinal Cord	69	0.5	0.4	0.6
	Spinal Meninges	28	0.3	0.2	0.2
	Total	1,080	8.1	9.0	8.9
Female	Brain	163	0.9	1.2	1.4
	Intracranial Meninges	1,023	6.8	6.8	6.2
	Cranial Nerves and other CNS	175	1.1	1.4	1.1
	Tumors of the Sellar Region	310	2.0	2.4	2.3
	Spinal Cord	80	0.3	0.7	0.7
	Spinal Meninges	85	0.6	0.5	0.5
	Total	1,836	11.9	13.0	12.2
White	Brain	231	0.9	1.2	1.2
	Intracranial Meninges	1,178	5.1	5.2	4.9
	Cranial Nerves and other CNS	289	1.3	1.4	1.3
	Tumors of the Sellar Region	416	1.8	2.0	2.1
	Spinal Cord	125	0.4	0.6	0.7
	Spinal Meninges	102	0.5	0.4	0.4
	Total	2,341	10.1	10.8	10.6
Black	Brain	35	0.5	1.0	1.5
	Intracranial Meninges	164	6.0	5.0	4.8
	Cranial Nerves and other CNS	10	-	-	-
	Tumors of the Sellar Region	130	3.1	5.0	3.3
	Spinal Cord	12	-	0.4	0.4
	Spinal Meninges	5	-	-	-
	Total	356	10.4	11.7	10.4

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 9. Comparative Incidence Rates, New Jersey and U.S., 2001-2005
Males**

Cancer Site	New Jersey 2001-2005			United States 2001-2005		
	All Races Combined	White	Black	All Races Combined	White	Black
Population:						
All Sites	612.5	608.5	673.7	562.3	557.0	635.6
Colorectal	68.3	68.1	74.3	61.2	60.6	69.4
Lung	80.9	80.7	97.2	87.3	86.9	106.8
Prostate	183.9	171.6	269.6	158.2	149.8	236.3
Melanoma	25.5	29.4	1.1	22.1	24.2	1.1
Thyroid	5.9	6.2	3.2	4.6	4.8	2.5
Non-Hodgkin Lymphoma	25.9	26.5	20.6	23.2	23.7	17.0

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 10. Comparative Incidence Rates, New Jersey and U.S., 2001-2005
Females**

Cancer Site	New Jersey 2001-2005			United States 2001-2005		
	All Races Combined	White	Black	All Races Combined	White	Black
Population:						
All Sites	451.5	465.2	405.2	417.3	423.4	389.9
Colorectal	50.0	49.6	54.2	41.8	44.0	52.4
Lung	56.0	58.1	52.6	55.4	57.0	51.1
Breast (invasive)	129.8	134.7	110.0	123.6	125.9	111.4
Endometrial (Corpus Uteri)	27.6	29.1	21.4	23.1	23.7	19.2
Melanoma	16.1	19.3	1.0	14.3	16.0	1.0
Thyroid	17.4	18.8	9.5	13.4	13.9	8.2
Non-Hodgkin Lymphoma	17.7	18.4	12.6	16.3	16.8	11.5

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Table 11. Age-adjusted Mortality Rates, Males All Races Combined

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
All Sites	34,347	237.4	236.1	221.6	220.7
Oral Cavity and Pharynx	580	3.6	4.0	3.5	3.5
Lip	-	-	-	-	-
Tongue	172	0.9	1.2	1.2	1.0
Salivary Gland	55	0.6	0.4	0.2	0.3
Floor of Mouth	9	-	-	-	-
Gum and Other Mouth	65	0.5	0.5	0.4	0.3
Nasopharynx	47	-	0.4	0.3	0.3
Tonsil	40	0.2	0.2	0.2	0.3
Oropharynx	57	0.2	0.4	0.3	0.4
Hypopharynx	18	-	0.1	-	0.1
Digestive System	9,270	62.7	63.9	58.8	59.0
Esophagus	1,169	7.4	7.4	7.0	8.0
Stomach	1,052	7.6	7.2	6.9	6.3
Small Intestine	72	0.5	0.6	0.3	0.4
Colon and Rectum	3,640	26.6	26.0	23.0	22.4
Colon excluding Rectum	3,022	22.1	22.0	19.3	18.4
Rectum and Rectosigmoid Junction	618	4.5	3.9	3.7	4.0
Anus, Anal Canal and Anorectum	21	0.1	0.1	0.1	0.1
Liver and Intrahepatic Bile Duct	1,160	6.5	7.8	7.2	8.0
Liver	964	5.5	6.4	6.0	6.5
Intrahepatic Bile Duct	196	1.0	1.4	1.2	1.5
Gallbladder	89	0.5	0.7	0.7	0.5
Pancreas	1,910	12.4	12.8	12.8	12.2
Respiratory System	10,116	68.1	69.1	64.4	64.5
Larynx	382	2.4	2.5	2.6	2.4
Lung and Bronchus	9,640	65.1	66.0	61.3	61.4
Bones and Joints	52	0.2	0.3	0.4	0.3
Soft Tissue (Including Heart)	212	1.3	1.4	1.1	1.6
Skin (Excluding Basal and Squamous)	785	5.2	4.7	5.3	5.3
Melanoma of the Skin	607	4.0	3.7	3.8	4.1

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 11 (continued). Age-adjusted Mortality Rates, Males All Races Combined

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
Breast	88	0.6	0.4	0.7	0.7
Male Genital System	3,541	26.6	27.5	24.7	24.0
Prostate	3,474	26.3	26.9	24.2	23.7
Testis	36	0.2	0.3	0.2	0.1
Penis	28	-	0.2	0.2	0.2
Urinary System	2,108	15.7	13.7	13.9	14.2
Urinary Bladder	1,174	8.3	7.4	8.5	8.7
Kidney and Renal Pelvis	890	7.0	5.9	5.1	5.2
Ureter	20	0.2	-	0.2	-
Eye	12	-	-	-	-
Brain and Other Nervous System	744	4.5	4.6	4.6	4.7
Endocrine System	128	0.9	0.8	1.0	0.6
Thyroid	71	0.4	0.4	0.7	0.3
Lymphomas	1,550	11.2	10.7	10.2	8.9
Hodgkin Lymphoma	96	0.6	0.5	0.7	0.5
Non-Hodgkin Lymphoma	1,454	10.5	10.2	9.4	8.4
Multiple Myeloma	647	4.7	4.8	3.7	4.2
Leukemias	1,470	10.6	10.1	9.7	9.2
Lymphocytic Leukemia	431	3.2	3.2	2.5	2.8
Acute Lymphocytic Leukemia	95	0.7	0.6	0.5	0.5
Chronic Lymphocytic Leukemia	313	2.3	2.3	2.0	2.2
Myeloid and Monocytic Leukemia	665	4.9	4.3	4.5	4.0
Acute Myeloid Leukemia	558	3.8	3.7	3.8	3.6
Acute Monocytic Leukemia	7	-	-	-	0.0
Chronic Myeloid Leukemia	71	0.8	0.5	0.4	0.2
Other Leukemia	374	2.5	2.6	2.6	2.5
Ill-Defined & Unspecified Sites	3,044	21.6	20.1	19.5	20.1

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12. Age-adjusted Mortality Rates, Females All Races Combined

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
All Sites	35,814	172.8	171.4	164.3	160.4
Oral Cavity and Pharynx	301	1.5	1.4	1.4	1.3
Lip	-	-	0.0	-	-
Tongue	88	0.4	0.4	0.4	0.4
Salivary Gland	26	0.1	0.1	0.1	0.1
Floor of Mouth	6	0.0	-	0.0	-
Gum and Other Mouth	50	0.3	0.3	0.2	0.1
Nasopharynx	27	0.2	0.1	0.1	-
Tonsil	15	-	-	0.1	-
Oropharynx	27	0.1	0.1	0.1	0.2
Hypopharynx	9	-	-	-	-
Digestive System	8,415	39.0	39.7	38.1	36.3
Esophagus	397	2.0	1.8	1.9	1.8
Stomach	754	3.5	3.4	3.3	3.7
Small Intestine	68	0.3	0.3	0.2	0.3
Colon and Rectum	3,902	18.0	19.2	16.4	16.3
Colon excluding Rectum	3,383	15.4	16.7	14.2	14.1
Rectum and Rectosigmoid Junction	519	2.5	2.5	2.2	2.2
Anus, Anal Canal and Anorectum	42	0.1	0.3	0.3	0.1
Liver and Intrahepatic Bile Duct	640	2.5	3.0	3.5	2.8
Liver	427	1.6	2.0	2.4	1.9
Intrahepatic Bile Duct	213	0.9	1.1	1.1	0.9
Gallbladder	212	0.9	1.0	1.1	0.9
Pancreas	2,159	10.4	9.7	10.2	9.3
Respiratory System	8,639	41.6	41.5	40.9	39.9
Larynx	102	0.5	0.4	0.4	0.6
Lung and Bronchus	8,505	40.9	41.1	40.3	39.0
Bones and Joints	57	0.2	0.3	0.4	0.2
Soft Tissue (Including Heart)	262	1.3	1.1	1.1	1.6
Skin (Excluding Basal and Squamous)	454	2.0	2.0	2.2	2.3
Melanoma of the Skin	368	1.7	1.7	1.8	1.9
Breast	5,796	28.5	28.7	26.0	26.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12 (continued). Age-adjusted Mortality Rates, Females All Races Combined

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
Female Genital System	3,715	18.7	18.5	16.9	16.6
Cervix Uteri	515	2.4	2.7	2.6	2.6
Corpus and Uterus, NOS	1,082	5.3	5.0	5.0	5.0
Corpus Uteri	468	2.6	2.2	2.3	1.9
Uterus, NOS	614	2.7	2.9	2.7	3.1
Ovary	1,941	10.1	9.8	8.6	8.3
Vagina	44	0.1	0.2	0.2	0.2
Vulva	97	0.5	0.4	0.4	0.4
Urinary System	1,212	5.9	5.7	5.2	5.1
Urinary Bladder	605	2.8	2.6	2.7	2.5
Kidney and Renal Pelvis	563	2.8	2.8	2.3	2.5
Ureter	30	0.2	0.2	0.1	0.1
Eye	15	0.1	0.1	-	-
Brain and Other Nervous System	597	2.9	2.5	3.3	3.0
Endocrine System	173	0.6	0.8	1.1	0.8
Thyroid	116	0.4	0.5	0.7	0.5
Lymphomas	1,369	6.8	6.2	6.3	5.8
Hodgkin Lymphoma	87	0.5	0.5	0.4	0.4
Non-Hodgkin Lymphoma	1,282	6.3	5.7	5.9	5.5
Multiple Myeloma	661	3.1	3.4	2.9	2.9
Leukemias	1,225	6.1	5.7	5.8	5.0
Lymphocytic Leukemia	329	1.6	1.6	1.3	1.5
Acute Lymphocytic Leukemia	80	0.4	0.4	0.4	0.5
Chronic Lymphocytic Leukemia	234	1.1	1.1	0.8	1.0
Myeloid and Monocytic Leukemia	542	2.7	2.7	2.8	2.2
Acute Myeloid Leukemia	455	2.2	2.4	2.4	1.8
Acute Monocytic Leukemia	5	-	-	-	0.0
Chronic Myeloid Leukemia	57	0.3	0.2	0.2	0.3
Other Leukemia	354	1.8	1.5	1.8	1.3
Ill-Defined & Unspecified Sites	2,923	14.4	13.8	12.7	12.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 13. Age-adjusted Mortality Rates, White Males

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
All Sites	29,484	235.2	234.6	220.0	221.8
Oral Cavity and Pharynx	452	3.2	3.9	3.4	2.9
Lip	-	-	-	-	-
Tongue	143	0.8	1.3	1.2	0.9
Salivary Gland	52	0.6	0.4	0.2	0.3
Floor of Mouth	5	-	0.0	-	-
Gum and Other Mouth	50	0.4	0.4	0.4	0.3
Nasopharynx	32	-	0.4	0.3	0.2
Tonsil	30	0.2	0.3	0.2	0.2
Oropharynx	43	0.2	0.4	0.3	0.4
Hypopharynx	12	-	-	-	-
Digestive System	7,840	61.4	62.9	57.4	58.6
Esophagus	1,006	7.6	7.3	7.1	8.1
Stomach	839	6.8	6.8	6.3	6.0
Small Intestine	57	0.5	0.5	0.3	0.5
Colon and Rectum	3,134	26.5	26.1	22.8	22.2
Colon excluding Rectum	2,597	21.8	22.1	19.2	18.0
Rectum and Rectosigmoid Junction	537	4.8	3.9	3.5	4.1
Anus, Anal Canal and Anorectum	18	0.2	-	-	0.1
Liver and Intrahepatic Bile Duct	905	6.0	7.2	6.5	7.4
Liver	728	4.9	5.8	5.2	5.9
Intrahepatic Bile Duct	177	1.1	1.5	1.3	1.5
Gallbladder	73	0.4	0.7	0.7	0.5
Pancreas	1,669	12.4	12.9	12.8	12.7
Respiratory System	8,683	67.5	68.5	64.1	65.1
Larynx	289	2.1	2.2	2.4	2.0
Lung and Bronchus	8,312	64.8	65.8	61.1	62.4
Bones and Joints	43	0.2	0.4	0.5	0.3
Soft Tissue (Including Heart)	176	1.2	1.5	1.1	1.6
Skin (Excluding Basal and Squamous)	769	6.0	5.3	6.0	6.1
Melanoma of the Skin	600	4.7	4.2	4.5	4.8

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 13 (continued). Age-adjusted Mortality Rates, White Males

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
Breast	72	0.5	0.4	0.7	0.6
Male Genital System	2,875	24.5	25.3	22.3	22.4
Prostate	2,814	24.1	24.7	21.8	22.0
Testis	35	0.3	0.3	0.3	0.2
Penis	25	-	0.2	0.2	0.2
Urinary System	1,932	16.5	14.4	14.7	15.0
Urinary Bladder	1,103	8.9	8.0	8.9	9.4
Kidney and Renal Pelvis	788	7.2	5.9	5.6	5.4
Ureter	20	0.2	-	0.2	-
Eye	12	-	-	-	-
Brain and Other Nervous System	680	4.8	5.1	5.2	5.1
Endocrine System	106	0.7	0.8	1.1	0.6
Thyroid	63	0.4	0.5	0.7	0.3
Lymphomas	1,374	11.4	11.3	10.5	9.3
Hodgkin Lymphoma	80	0.7	0.6	0.7	0.5
Non-Hodgkin Lymphoma	1,294	10.7	10.7	9.8	8.7
Multiple Myeloma	525	4.5	4.3	3.5	4.1
Leukemias	1,312	10.8	10.5	10.0	9.7
Lymphocytic Leukemia	388	3.3	3.4	2.6	2.9
Acute Lymphocytic Leukemia	79	0.8	0.6	0.5	0.5
Chronic Lymphocytic Leukemia	289	2.3	2.5	2.0	2.3
Myeloid and Monocytic Leukemia	589	4.9	4.4	4.6	4.2
Acute Myeloid Leukemia	506	4.0	3.7	4.0	3.9
Acute Monocytic Leukemia	5	0.0	-	-	0.0
Chronic Myeloid Leukemia	52	0.6	0.5	0.4	0.2
Other Leukemia	335	2.6	2.7	2.8	2.6
Ill-Defined and Unspecified Sites	2,633	21.8	19.9	19.5	20.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 14. Age-adjusted Mortality Rates, White Females

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
All Sites	30,969	173.9	172.4	166.1	162.0
Oral Cavity and Pharynx	242	1.4	1.3	1.3	1.3
Lip	-	-	-	-	-
Tongue	71	0.4	0.3	0.4	0.4
Salivary Gland	21	0.1	-	0.2	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	45	0.3	0.3	0.2	0.1
Nasopharynx	16	0.1	-	-	-
Tonsil	13	-	-	0.1	-
Oropharynx	22	0.1	0.1	-	0.2
Hypopharynx	8	-	-	-	-
Digestive System	7,211	38.4	39.0	37.7	35.7
Esophagus	342	2.0	1.8	1.9	1.7
Stomach	601	3.3	3.1	3.1	3.3
Small Intestine	61	0.3	0.4	0.3	0.3
Colon and Rectum	3,365	17.9	18.7	16.5	16.1
Colon excluding Rectum	2,912	15.3	16.2	14.2	13.9
Rectum and Rectosigmoid Junction	453	2.6	2.5	2.3	2.1
Anus, Anal Canal and Anorectum	36	0.1	0.3	0.2	0.2
Liver and Intrahepatic Bile Duct	542	2.5	3.1	3.3	2.6
Liver	357	1.6	2.0	2.2	1.8
Intrahepatic Bile Duct	185	0.9	1.1	1.1	0.8
Gallbladder	179	0.9	1.0	1.0	0.9
Pancreas	1,868	10.3	9.6	10.1	9.5
Respiratory System	7,578	42.8	42.3	41.9	41.2
Larynx	77	0.5	0.3	0.4	0.6
Lung and Bronchus	7,474	42.1	42.0	41.4	40.4
Bones and Joints	48	0.3	0.3	0.3	0.2
Soft Tissue (Including Heart)	220	1.1	1.2	1.3	1.5
Skin (Excluding Basal and Squamous)	437	2.2	2.3	2.6	2.6
Melanoma of the Skin	360	1.9	2.0	2.1	2.2
Breast	4,894	28.2	28.6	25.7	26.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 14 (continued). Age-adjusted Mortality Rates, White Females

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
Female Genital System	3,151	18.5	18.3	17.0	16.8
Cervix Uteri	377	2.0	2.3	2.4	2.5
Corpus and Uterus, NOS	888	5.0	4.8	4.9	4.7
Corpus Uteri	403	2.5	2.1	2.3	2.1
Uterus, NOS	485	2.5	2.7	2.6	2.6
Ovary	1,733	10.5	10.3	9.2	8.9
Vagina	34	0.1	0.2	0.2	0.2
Vulva	90	0.6	0.5	0.4	0.4
Urinary System	1,083	6.0	5.9	5.3	5.2
Urinary Bladder	536	2.8	2.6	2.7	2.5
Kidney and Renal Pelvis	510	3.0	3.0	2.4	2.6
Ureter	26	0.2	0.2	0.1	-
Eye	13	0.1	0.1	-	-
Brain and Other Nervous System	552	3.3	2.8	3.6	3.4
Endocrine System	148	0.7	0.8	1.1	0.7
Thyroid	101	0.4	0.5	0.7	0.5
Lymphomas	1,245	7.3	6.5	6.7	6.1
Hodgkin Lymphoma	78	0.6	0.5	0.5	0.3
Non-Hodgkin Lymphoma	1,167	6.7	5.9	6.2	5.7
Multiple Myeloma	506	2.9	3.0	2.6	2.5
Leukemias	1,095	6.4	6.0	5.9	5.2
Lymphocytic Leukemia	306	1.7	1.7	1.4	1.6
Acute Lymphocytic Leukemia	72	0.4	0.5	0.5	0.5
Chronic Lymphocytic Leukemia	220	1.2	1.1	0.9	1.1
Myeloid and Monocytic Leukemia	481	2.8	2.9	2.9	2.2
Acute Myeloid Leukemia	407	2.3	2.6	2.5	1.8
Acute Monocytic Leukemia	5	-	-	-	0.0
Chronic Myeloid Leukemia	48	0.3	0.2	0.2	0.2
Other Leukemia	308	1.9	1.4	1.6	1.4
Ill-Defined & Unspecified Sites	2,546	14.4	14.0	12.9	12.6

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 15. Age-adjusted Mortality Rates, Black Males

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
All Sites	4,126	298.9	312.5	282.0	262.0
Oral Cavity and Pharynx	108	6.9	5.2	5.4	8.0
Lip	-	-	-	-	-
Tongue	25	1.9	-	1.5	1.9
Salivary Gland	-	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	13	-	1.6	-	-
Nasopharynx	9	-	-	-	-
Tonsil	10	-	-	-	1.1
Oropharynx	13	-	-	-	-
Hypopharynx	5	-	-	-	-
Digestive System	1,138	77.8	84.1	76.7	71.0
Esophagus	148	8.7	10.8	8.1	9.6
Stomach	155	15.0	11.3	11.1	8.0
Small Intestine	14	-	1.2	-	-
Colon and Rectum	429	28.7	32.8	28.6	31.7
Colon excluding Rectum	360	26.1	27.5	23.5	27.2
Rectum and Rectosigmoid Junction	69	2.6	5.3	5.1	4.5
Anus, Anal Canal and Anorectum	-	-	-	-	-
Liver and Intrahepatic Bile Duct	169	8.3	12.4	11.6	8.4
Liver	155	7.8	11.6	11.1	7.3
Intrahepatic Bile Duct	14	-	-	-	1.1
Gallbladder	8	-	-	-	-
Pancreas	198	13.2	15.0	15.8	11.1
Respiratory System	1,261	86.5	93.9	83.1	78.1
Larynx	86	5.5	5.9	5.0	6.2
Lung and Bronchus	1,165	80.4	86.8	78.1	71.2
Bones and Joints	8	-	-	-	-
Soft Tissue (Including Heart)	27	1.7	1.1	1.6	1.7
Skin (Excluding Basal and Squamous)	14	-	-	1.1	-
Melanoma of the Skin	5	-	-	-	-

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 15 (continued). Age-adjusted Mortality Rates, Black Males

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
Breast	15	-	-	-	1.9
Male Genital System	627	58.5	61.1	54.4	47.6
Prostate	624	58.5	60.3	54.4	47.6
Testis	-	-	-	-	-
Penis	-	-	-	-	-
Urinary System	148	11.5	10.0	9.0	9.9
Urinary Bladder	58	4.3	2.6	6.0	4.3
Kidney and Renal Pelvis	87	6.7	7.1	2.9	5.6
Ureter	-	-	-	-	-
Eye	-	-	-	-	-
Brain and Other Nervous System	49	2.4	2.8	2.0	3.4
Endocrine System	15	1.5	-	-	-
Thyroid	6	-	-	-	-
Lymphomas	137	10.3	6.8	8.2	5.8
Hodgkin Lymphoma	8	-	-	0.9	-
Non-Hodgkin Lymphoma	129	10.3	6.5	7.4	5.5
Multiple Myeloma	109	6.2	10.6	7.5	5.8
Leukemias	127	10.7	8.5	7.6	7.1
Lymphocytic Leukemia	37	3.5	2.7	2.1	2.3
Acute Lymphocytic Leukemia	11	-	-	-	-
Chronic Lymphocytic Leukemia	23	2.7	1.6	1.9	-
Myeloid and Monocytic Leukemia	55	4.7	3.4	3.1	2.5
Acute Myeloid Leukemia	36	2.0	2.9	1.9	2.1
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	15	2.3	-	-	-
Other Leukemia	35	2.4	2.4	2.4	2.3
Ill-Defined & Unspecified Sites	343	23.2	26.5	22.7	20.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 16. Age-adjusted Mortality Rates, Black Females

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
All Sites	4,236	197.5	193.5	180.5	180.9
Oral Cavity and Pharynx	49	1.8	2.8	2.4	1.5
Lip	-	-	-	-	-
Tongue	12	-	-	-	-
Salivary Gland	-	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	-	-	-	-	-
Nasopharynx	8	-	-	-	-
Tonsil	-	-	-	-	-
Oropharynx	5	-	-	-	-
Hypopharynx	-	-	-	-	-
Digestive System	1,048	49.8	50.5	44.2	47.7
Esophagus	49	2.2	2.3	1.7	2.2
Stomach	129	6.1	5.1	5.2	7.2
Small Intestine	7	-	-	-	-
Colon and Rectum	491	23.1	26.1	18.7	22.6
Colon excluding Rectum	436	20.8	23.8	16.5	19.3
Rectum and Rectosigmoid Junction	55	2.2	2.3	2.2	3.3
Anus, Anal Canal and Anorectum	6	-	-	-	-
Liver and Intrahepatic Bile Duct	68	2.4	2.3	3.1	4.4
Liver	49	1.6	1.9	2.7	2.6
Intrahepatic Bile Duct	19	-	-	-	1.7
Gallbladder	30	1.8	1.1	1.6	0.9
Pancreas	252	12.6	12.3	12.8	9.2
Respiratory System	959	42.5	42.5	44.4	41.4
Larynx	25	1.1	1.1	0.9	1.2
Lung and Bronchus	931	41.3	41.2	43.3	40.0
Bones and Joints	8	-	-	0.7	-
Soft Tissue (Including Heart)	41	2.5	1.3	-	2.3
Skin (Excluding Basal and Squamous)	11	-	-	-	-
Melanoma of the Skin	-	-	-	-	-
Breast	786	36.3	34.5	33.3	29.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 16 (continued). Age-adjusted Mortality Rates, Black Females

Cancer Site	Total Cases	Rates			
		2002	2003	2004	2005
Female Genital System	492	24.6	23.3	19.9	17.9
Cervix Uteri	124	5.2	6.5	5.2	3.8
Corpus and Uterus, NOS	175	9.1	8.0	6.5	7.9
Corpus Uteri	60	4.1	3.2	2.9	1.0
Uterus, NOS	115	5.1	4.8	3.6	6.9
Ovary	171	9.4	7.6	7.2	5.7
Vagina	9	-	-	-	-
Vulva	6	-	-	-	-
Urinary System	117	6.9	4.7	5.3	4.9
Urinary Bladder	65	3.8	3.2	3.0	2.4
Kidney and Renal Pelvis	47	2.9	1.0	2.1	2.4
Ureter	-	-	-	-	-
Eye	-	-	-	-	-
Brain and Other Nervous System	32	1.3	1.4	1.8	0.9
Endocrine System	17	-	-	-	1.4
Thyroid	10	-	-	-	0.9
Lymphomas	96	4.0	4.0	3.6	5.1
Hodgkin Lymphoma	9	-	-	-	-
Non-Hodgkin Lymphoma	87	3.8	3.7	3.2	4.4
Multiple Myeloma	144	6.1	7.6	5.9	6.8
Leukemias	101	4.0	4.4	4.9	4.5
Lymphocytic Leukemia	20	1.1	1.2	-	1.1
Acute Lymphocytic Leukemia	7	-	-	-	-
Chronic Lymphocytic Leukemia	13	-	1.2	-	-
Myeloid and Monocytic Leukemia	42	1.3	1.8	1.7	2.4
Acute Myeloid Leukemia	31	1.0	1.7	1.4	1.4
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	7	-	-	-	-
Other Leukemia	39	1.7	1.4	2.9	1.0
Ill-Defined & Unspecified Sites	333	16.5	15.0	12.6	16.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17. Age-adjusted Mortality Rates, Hispanic Males and Females
2002-2005 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
All Sites	137.0	1,562	91.0	1,409
Oral Cavity and Pharynx	2.4	34	1.1	17
Lip	-	-	-	-
Tongue	0.6	11	-	-
Salivary Gland	-	-	-	-
Floor of Mouth	-	-	-	-
Gum and Other Mouth	-	-	-	-
Nasopharynx	-	-	-	-
Tonsil	0.3	5	-	-
Oropharynx	0.4	5	-	-
Hypopharynx	-	-	-	-
Digestive System	45.1	531	28.7	417
Esophagus	3.9	52	1.4	19
Stomach	9.1	108	4.4	69
Small Intestine	0.4	6	-	-
Colon and Rectum	16.9	186	9.9	140
Colon excluding Rectum	14.3	151	8.9	125
Rectum and Rectosigmoid Junction	2.7	35	1.0	15
Anus, Anal Canal and Anorectum	-	-	-	-
Liver and Intrahepatic Bile Duct	6.7	81	3.5	50
Liver	6.1	73	2.4	34
Intrahepatic Bile Duct	0.6	8	1.1	16
Gallbladder	0.4	6	1.6	25
Pancreas	7.0	84	7.2	102
Respiratory System	32.3	366	12.7	187
Larynx	1.4	19	-	-
Lung and Bronchus	30.5	342	12.7	187
Bones and Joints	-	-	-	-
Soft Tissue (Including Heart)	0.7	9	0.6	12
Skin (Excluding Basal and Squamous)	0.6	10	0.6	9
Melanoma of the Skin	0.3	6	0.4	6
Breast	-	-	13.4	234

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females
2002-2005 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
Female Genital System	*	*	11.0	181
Cervix Uteri	*	*	2.5	50
Corpus and Uterus, NOS	*	*	3.4	51
Corpus Uteri	*	*	1.5	21
Uterus, NOS	*	*	2.0	30
Ovary	*	*	4.0	66
Vagina	*	*	-	-
Vulva	*	*	0.6	8
Male Genital System	18.9	165	*	*
Prostate	18.3	154	*	*
Testis	-	-	*	*
Penis	0.5	9	*	*
Urinary System	7.8	76	2.5	38
Urinary Bladder	4.7	43	1.5	21
Kidney and Renal Pelvis	2.8	30	0.9	15
Ureter	-	-	-	-
Eye	-	-	-	-
Brain and Other Nervous System	2.5	35	1.6	29
Endocrine System	-	-	0.5	8
Thyroid	-	-	-	-
Lymphomas	6.5	82	5.0	73
Hodgkin Lymphoma	0.3	5	0.4	7
Non-Hodgkin Lymphoma	6.2	77	4.7	66
Multiple Myeloma	2.6	31	2.8	39
Leukemias	4.3	68	3.5	60
Lymphocytic Leukemia	1.1	21	1.0	18
Acute Lymphocytic Leukemia	0.5	14	0.7	14
Chronic Lymphocytic Leukemia	0.6	6	-	-
Myeloid and Monocytic Leukemia	2.0	30	1.6	30
Acute Myeloid Leukemia	1.7	23	1.3	25
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	0.3	7	-	-
Other Leukemia	1.1	17	0.9	12
Ill-Defined & Unspecified Sites	12.9	147	6.8	101

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 18. Comparative Mortality Rates, New Jersey and U.S., 2001-2005
Males**

Cancer Site	New Jersey 2001-2005			United States 2001-2005			
	Population:	All Races Combined	White	Black	All Races Combined	White	Black
All Sites		232.4	230.9	296.2	234.4	230.7	313.0
Lung		64.8	64.7	82.2	72.0	71.3	93.1
Prostate		26.2	24.0	57.7	26.7	24.6	59.4
Colorectal		24.9	24.8	30.8	22.7	22.1	31.8

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 19. Comparative Mortality Rates, New Jersey and U.S., 2001-2005
Females**

Cancer Site	New Jersey 2001-2005			United States 2001-2005			
	Population:	All Races Combined	White	Black	All Races Combined	White	Black
All Sites		169.2	170.5	188.6	159.9	159.2	186.7
Lung		40.4	41.6	41.1	41.0	42.0	39.9
Breast		27.8	27.6	33.1	25.0	24.4	33.5
Colorectal		17.9	17.7	22.7	15.9	15.3	22.4

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Cancer Incidence and Mortality in New Jersey, 2002-2006

Table 20. Population Denominators

	2001						2002					
	All Races		White	White	Black	Black	All Races		White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	56,816	53,898	41,451	39,208	10,799	10,535	57,122	54,705	41,947	39,908	10,708	10,352
01-04	229,359	219,332	171,118	162,827	40,411	39,209	228,947	218,537	169,804	161,321	40,928	39,636
05-09	305,357	291,159	227,385	216,584	55,942	53,427	302,201	288,094	224,969	213,828	54,481	52,156
10-14	309,939	295,297	233,098	221,244	56,088	54,652	314,687	299,633	235,964	223,709	57,044	55,573
15-19	279,069	261,082	210,415	195,647	49,666	47,913	283,034	266,120	213,675	199,849	50,168	48,662
20-24	249,036	238,357	184,754	173,214	46,085	46,584	253,121	239,560	187,200	174,564	47,228	46,477
25-29	265,040	262,156	196,288	188,488	42,199	46,538	262,963	258,988	194,308	185,112	41,938	46,164
30-34	317,940	322,756	240,568	239,109	47,977	53,815	315,957	317,877	236,080	232,264	47,909	53,566
35-39	356,250	362,797	277,601	277,940	50,340	56,775	349,706	357,997	270,411	272,404	49,827	56,244
40-44	356,343	366,381	284,764	287,515	46,055	52,586	360,771	369,114	287,119	288,110	47,048	53,624
45-49	308,895	322,988	251,372	257,399	36,535	43,743	319,869	332,994	259,092	264,461	38,237	45,043
50-54	275,994	296,915	227,716	239,239	31,007	39,514	273,279	292,637	223,744	233,939	31,316	39,807
55-59	209,552	228,612	173,945	186,510	23,163	29,350	225,855	245,951	188,285	201,176	24,165	30,800
60-64	159,017	178,847	130,914	144,997	18,847	24,634	164,479	185,433	135,285	150,113	19,107	25,202
65-69	131,943	158,315	111,305	131,510	14,573	19,988	132,123	157,803	110,790	130,226	14,605	20,201
70-74	120,276	157,400	106,026	136,961	10,633	15,478	118,512	154,708	103,575	133,443	10,936	15,855
75-79	95,410	142,933	85,811	127,486	7,256	12,003	95,611	141,979	85,786	126,043	7,329	12,205
80-84	61,231	107,707	56,146	98,046	3,836	7,724	63,071	109,498	57,579	99,344	4,087	7,961
85+	41,043	100,202	37,671	91,633	2,580	7,215	42,700	102,691	39,110	93,767	2,669	7,372
Total	4,128,510	4,367,134	3,248,348	3,415,557	593,992	661,683	4,164,008	4,394,319	3,264,723	3,423,581	599,730	666,900

	2003						2004					
	All Races		White	White	Black	Black	All Races		White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	58,886	55,619	42,987	40,426	10,981	10,521	58,809	56,450	42,822	41,260	10,892	10,440
01-04	229,020	218,380	169,197	160,412	41,376	40,128	230,698	219,721	169,474	160,794	42,096	40,622
05-09	297,968	284,349	221,740	210,884	53,027	50,736	293,935	280,244	218,855	207,482	51,637	49,492
10-14	315,996	300,969	236,320	224,065	57,227	55,863	314,111	299,154	234,062	222,314	56,995	55,162
15-19	286,935	270,226	216,535	203,014	50,847	49,292	292,840	276,230	220,821	207,219	51,960	50,660
20-24	259,621	243,669	191,729	177,766	48,761	47,357	265,060	250,690	196,525	184,585	49,363	47,205
25-29	262,464	255,828	194,104	183,006	42,227	45,364	260,884	249,579	192,013	177,369	43,191	45,581
30-34	310,378	311,648	229,499	224,620	47,108	53,359	303,714	304,026	222,190	216,969	46,326	52,157
35-39	342,421	350,196	262,821	264,595	49,109	55,072	334,399	340,905	254,735	255,232	47,962	54,017
40-44	362,231	370,392	286,559	287,513	47,699	54,354	364,139	371,315	286,081	286,134	48,552	55,383
45-49	329,488	341,672	265,873	270,234	39,727	46,629	336,981	349,626	270,923	275,614	40,867	47,879
50-54	275,455	295,200	224,860	235,209	31,473	40,211	282,670	299,669	230,246	238,529	32,500	40,536
55-59	231,754	251,931	192,238	204,953	24,964	31,715	239,687	260,984	198,270	211,409	25,797	33,119
60-64	174,372	195,802	144,236	159,086	19,444	25,861	179,150	202,200	148,354	164,278	19,506	26,274
65-69	134,007	159,459	111,617	130,842	14,921	20,678	137,046	161,249	113,590	131,788	15,292	21,006
70-74	116,603	151,179	101,148	129,294	11,038	16,114	113,915	147,865	97,981	125,174	11,121	16,499
75-79	95,416	140,848	85,214	124,414	7,497	12,366	94,725	137,939	84,254	121,167	7,539	12,379
80-84	63,850	110,466	58,061	99,750	4,221	8,295	65,169	112,518	59,115	101,257	4,341	8,663
85+	44,834	105,458	40,963	96,256	2,820	7,443	46,025	106,914	41,814	97,345	3,019	7,606
Total	4,191,699	4,413,291	3,275,701	3,426,339	604,467	671,358	4,213,957	4,427,278	3,282,125	3,425,919	608,956	674,680

	2005						2006					
	All Races		White	White	Black	Black	All Races		White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	56,719	54,078	41,052	39,077	10,579	10,193	55,749	53,086	39,867	37,732	10,914	10,585
01-04	231,428	220,181	168,939	160,542	42,796	40,991	229,922	219,223	167,505	159,682	42,299	40,326
05-09	289,529	276,610	215,646	204,593	50,053	48,424	285,588	272,274	211,615	200,329	49,835	48,493
10-14	309,375	293,967	230,057	218,077	55,913	53,608	304,318	289,543	225,960	214,463	54,384	51,986
15-19	299,320	282,171	225,073	211,162	53,506	52,110	302,898	285,726	227,461	213,228	54,212	52,982
20-24	270,231	254,813	201,307	189,048	49,688	46,840	275,673	260,840	206,631	195,084	49,787	47,015
25-29	260,193	248,658	190,388	176,432	44,239	45,860	259,897	247,171	188,940	174,571	46,050	46,526
30-34	294,006	292,424	213,613	206,511	44,839	50,120	284,550	281,011	205,967	196,934	43,020	48,199
35-39	329,726	334,576	248,856	248,146	47,342	53,520	325,707	330,117	243,310	242,542	47,222	52,933
40-44	361,959	368,334	282,758	282,349	48,763	55,196	356,317	362,566	276,267	275,717	48,330	55,139
45-49	343,369	355,670	274,087	278,928	42,684	49,628	348,868	360,270	277,594	281,694	43,838	50,616
50-54	290,108	305,064	236,590	242,893	32,865	40,581	298,018	311,804	242,075	247,459	34,023	41,449
55-59	249,287	271,476	205,238	218,725	27,127	34,944	258,091	279,754	212,163	224,660	28,119	36,442
60-64	183,474	205,986	152,061	167,367	19,658	26,157	187,965	211,219	155,750	171,714	19,674	26,110
65-69	138,848	163,057	114,518	132,535	15,448	21,526	140,389	165,535	115,549	134,135	15,534	21,798
70-74	111,988	144,962	95,616	121,557	11,207	16,724	111,697	142,976	94,404	118,659	11,502	17,258
75-79	94,186	135,609	83,229	118,409	7,740	12,530	93,024	133,698	82,016	116,204	7,609	12,549
80-84	65,189	112,140	58,832	100,502	4,503	8,786	65,018	110,730	58,414	98,664	4,624	8,991
85+	48,264	110,470	43,707	100,216	3,200	8,020	50,682	114,161	45,837	103,548	3,356	8,169
Total	4,227,199	4,430,246	3,281,567	3,417,069	612,150	675,758	4,234,371	4,431,704	3,277,325	3,407,019	614,332	677,566

Source: The National Cancer Institute's SEER Program and National Center for Health Statistics (URL: <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>).

Cancer Incidence and Mortality in New Jersey, 2002-2006

Table 20 (continued). Population Denominators

Hispanic Population, 2002-2006

	Male Total	Male 2002	Male 2003	Male 2004	Male 2005	Male 2006	Female Total	Female 2002	Female 2003	Female 2004	Female 2005	Female 2006
<1	66,183	11,743	12,881	13,636	13,763	14,160	63,306	11,154	12,044	13,296	13,261	13,551
00-04	235,508	42,830	44,576	47,281	49,452	51,369	223,914	40,781	42,312	44,592	47,049	49,180
05-09	260,909	51,076	51,664	51,885	52,681	53,603	248,575	48,771	49,222	49,608	50,224	50,750
10-14	258,588	49,978	51,226	52,242	52,498	52,644	247,003	48,245	49,168	49,829	49,664	50,097
15-19	244,449	47,197	47,474	48,286	50,103	51,389	231,575	43,673	44,870	46,029	47,897	49,106
20-24	295,111	59,924	60,298	59,614	58,226	57,049	250,354	49,652	50,014	50,431	50,327	49,930
25-29	322,632	61,161	63,437	64,867	66,140	67,027	265,091	51,953	52,911	52,799	53,404	54,024
30-34	313,273	59,767	61,406	63,068	63,972	65,060	280,263	54,452	55,375	56,709	56,857	56,870
35-39	295,108	56,770	58,084	58,884	60,155	61,215	275,772	53,969	54,697	54,883	55,706	56,517
40-44	263,136	47,679	50,470	53,157	55,087	56,743	252,651	46,519	49,166	51,042	52,296	53,628
45-49	202,974	36,079	38,315	40,362	42,925	45,293	207,054	37,398	39,286	41,434	43,585	45,351
50-54	150,944	27,286	28,415	30,035	31,590	33,618	160,118	29,345	30,492	31,967	33,333	34,981
55-59	115,152	20,466	21,680	23,047	24,469	25,490	128,486	22,989	24,323	25,622	27,323	28,229
60-64	81,681	15,083	15,805	16,148	16,907	17,738	96,013	17,430	18,378	19,234	19,833	21,138
65-69	60,996	10,732	11,494	12,346	12,975	13,449	74,256	13,553	14,183	14,823	15,523	16,174
70-74	41,631	7,523	7,882	8,235	8,765	9,226	55,831	10,160	10,629	11,142	11,752	12,148
75-79	26,951	4,613	4,988	5,393	5,784	6,173	39,538	6,925	7,410	7,970	8,355	8,878
80-84	14,999	2,450	2,732	3,008	3,259	3,550	25,226	4,372	4,735	5,042	5,419	5,658
85+	10,713	1,752	1,916	2,100	2,343	2,602	23,117	3,852	4,223	4,608	4,992	5,442
Total	3,260,938	614,109	634,743	653,594	671,094	687,398	3,148,143	595,193	613,438	631,060	646,800	661,652

Source: The National Cancer Institute's SEER Program and National Center for Health Statistics (URL: <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>).

**Table 21. Age Distribution (%) of Incidence Cases in New Jersey, 2002-2006
All Races, Both Sexes**

Cancer Site	0-19	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.9%	2.4%	5.7%	13.2%	21.4%	24.9%	23.7%	7.8%	100%	230,667
Male	1.0%	1.9%	3.8%	11.2%	23.2%	28.5%	24.3%	6.2%	100%	117,279
Female	0.9%	2.9%	7.6%	15.3%	19.5%	21.2%	23.1%	9.5%	100%	113,388
Oral Cavity and Pharynx	0.4%	2.0%	6.9%	20.4%	25.0%	22.6%	16.7%	5.9%	100%	4,540
Esophagus	0.0%	0.4%	2.2%	12.6%	24.1%	27.9%	25.1%	7.7%	100%	2,290
Stomach	0.2%	1.3%	4.4%	10.0%	17.2%	24.7%	29.8%	12.5%	100%	4,121
Colon and Rectum	0.0%	0.9%	3.4%	10.2%	17.4%	23.9%	30.8%	13.3%	100%	25,519
Male	0.0%	0.8%	3.6%	11.0%	20.2%	26.7%	28.8%	8.9%	100%	12,646
Female	0.0%	1.0%	3.2%	9.5%	14.7%	21.2%	32.9%	17.6%	100%	12,873
Colon excluding Rectum	0.0%	0.9%	2.9%	8.9%	15.9%	23.9%	32.7%	14.9%	100%	18,396
Rectum	0.0%	1.0%	4.7%	13.5%	21.3%	24.1%	26.0%	9.3%	100%	7,123
Liver and Intrahepatic Bile Duct	0.7%	1.1%	3.2%	17.7%	23.7%	23.1%	22.9%	7.5%	100%	2,773
Pancreas	0.1%	0.4%	2.2%	8.5%	19.1%	25.6%	31.3%	12.8%	100%	5,676
Lung and Bronchus	0.0%	0.2%	2.0%	8.7%	21.0%	30.2%	30.1%	7.8%	100%	29,950
Male	0.0%	0.2%	1.7%	8.5%	21.9%	30.9%	30.0%	6.7%	100%	15,407
Female	0.0%	0.2%	2.3%	8.9%	20.0%	29.3%	30.2%	9.1%	100%	14,543
Bones and Joints	26.7%	15.5%	13.5%	13.0%	9.9%	8.8%	8.8%	3.8%	100%	453
Soft Tissue including Heart	6.8%	10.2%	13.0%	14.2%	15.2%	16.3%	17.5%	7.0%	100%	1,490
Melanoma of the Skin	0.8%	6.0%	11.9%	17.0%	18.6%	20.1%	19.1%	6.6%	100%	9,348
Breast (female)	0.0%	1.8%	10.9%	22.0%	22.6%	19.5%	17.4%	5.8%	100%	32,186
Cervix Uteri	0.1%	11.5%	24.4%	25.7%	16.1%	11.8%	7.7%	2.7%	100%	2,183
Corpus and Uterus, NOS	0.0%	1.0%	4.9%	17.1%	30.8%	24.1%	17.0%	5.1%	100%	7,225
Ovary	1.2%	3.0%	7.5%	19.4%	22.6%	18.9%	19.2%	8.2%	100%	3,659
Prostate	0.0%	0.0%	0.7%	8.8%	29.0%	35.4%	22.0%	4.0%	100%	35,369
Testis	5.1%	43.7%	29.5%	15.4%	4.0%	1.2%	0.9%	0.2%	100%	1,216
Urinary Bladder	0.1%	0.4%	1.9%	7.3%	18.4%	27.5%	32.6%	11.9%	100%	12,012
Kidney and Renal Pelvis	1.3%	1.6%	6.0%	15.3%	23.6%	25.2%	21.3%	5.6%	100%	6,812
Brain and Other Nervous System	12.4%	6.9%	9.6%	15.7%	16.9%	18.1%	15.3%	5.0%	100%	3,143
Thyroid	1.7%	15.3%	21.7%	24.1%	17.5%	11.1%	7.0%	1.5%	100%	5,731
Hodgkin Lymphoma	11.2%	30.6%	16.8%	13.1%	9.8%	9.4%	7.0%	2.3%	100%	1,462
Non-Hodgkin Lymphoma	1.6%	3.7%	7.2%	13.5%	18.2%	21.9%	25.4%	8.6%	100%	9,623
Myeloma	0.0%	0.8%	3.5%	12.6%	19.4%	26.8%	28.1%	9.0%	100%	2,811
Leukemia	9.1%	3.8%	5.0%	10.2%	16.0%	20.3%	25.7%	10.0%	100%	5,886
Acute Lymphocytic Leukemia	57.3%	8.6%	4.4%	6.0%	7.0%	7.9%	6.6%	2.2%	100%	698
Chronic Lymphocytic Leukemia	0.0%	0.3%	2.0%	9.6%	19.6%	25.5%	31.0%	12.1%	100%	2,056
Acute Myeloid Leukemia	5.0%	5.4%	6.2%	11.2%	15.7%	19.9%	27.0%	9.7%	100%	1,750
Chronic Myeloid Leukemia	1.9%	5.5%	9.2%	13.4%	18.7%	18.7%	24.4%	8.2%	100%	673
Other Leukemia	5.4%	4.8%	2.9%	7.6%	7.9%	21.9%	31.8%	17.8%	100%	315
Mesothelioma	0.0%	0.3%	1.4%	4.7%	12.3%	26.5%	42.1%	12.6%	100%	705
Kaposi Sarcoma	0.0%	12.2%	26.8%	16.5%	9.8%	7.1%	16.5%	11.0%	100%	254

**Table 22. Median Age of Cancer Patients at Diagnosis, New Jersey 2002-2006
By Primary Cancer Site, Race and Sex**

Cancer Site	All Races			Whites			Blacks		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	67	68	66	68	69	67	64	64	62
Oral Cavity and Pharynx	62	61	66	63	61	68	59	60	57
Esophagus	68	67	72	69	68	74	63	63	61
Stomach	72	70	75	73	71	76	70	68	73
Colon and Rectum	72	70	75	74	71	76	67	66	68
Colon excluding Rectum	74	72	76	75	73	77	68	67	68
Rectum	69	67	71	70	68	73	64	64	65
Liver and Intrahepatic Bile Duct	66	63	74	68	66	75	59	57	64
Pancreas	73	70	75	73	71	76	69	66	71
Lung and Bronchus	71	71	71	71	71	72	66	66	67
Bones and Joints	40	38	44	43	41	47	34	28	41
Soft Tissue including Heart	59	59	59	61	61	61	46	45	46
Melanoma of the Skin	62	65	58	62	65	58	69	66	70
Breast	61	69	61	62	70	62	58	63	58
Cervix Uteri	*	*	50	*	*	50	*	*	50
Corpus and Uterus, NOS	*	*	63	*	*	63	*	*	64
Ovary	*	*	63	*	*	63	*	*	61
Prostate	*	68	*	*	68	*	*	65	*
Testis	*	35	*	*	35	*	*	35	*
Urinary Bladder	73	72	74	73	73	74	70	68	72
Kidney and Renal Pelvis	65	64	67	66	65	68	62	61	63
Brain and Other Nervous System	58	57	59	59	58	61	51	50	52
Thyroid	49	53	48	49	54	48	51	55	50
Hodgkin Lymphoma	40	40	39	40	41	39	39	39	39
Non-Hodgkin Lymphoma	67	65	70	69	67	71	55	54	58
Myeloma	70	68	71	71	69	72	67	67	69
Leukemia	68	66	70	69	68	71	60	60	60
Acute Lymphocytic Leukemia	14	15	14	15	15	14	13	12	18
Chronic Lymphocytic Leukemia	72	70	75	73	71	75	67	66	68
Acute Myeloid Leukemia	68	68	69	70	70	70	58	58	60
Chronic Myeloid Leukemia	65	66	64	68	67	71	58	59	55
Other Leukemia	74	73	75	76	75	78	67	52	70
Mesothelioma	76	76	76	76	76	76	74	74	73
Kaposi Sarcoma	51	46	80	65	58	82	41	41	42

* Non-applicable gender.